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Abstract 
Microvascular blood flow is important to deliver key nutrients (e.g. oxygen, lipids and 
glucose) and hormones (e.g. insulin) to and remove waste products from adipose tissue. 
Total adipose tissue blood flow (ATBF) increases after a meal, and this response is 
impaired in obesity and type 2 diabetes (T2D). Microvascular blood flow is more 
important than total blood flow for nutrient exchange in many tissues, however it is not 
known whether microvascular blood flow in adipose tissue is altered by meals or T2D. 
Chronic exercise training improves microvascular blood flow in skeletal muscle of 
people with T2D. Whether adipose tissue microvascular responses are similarly 
improved following exercise training in people with T2D is unknown. The overarching 
goal of the current thesis is to characterise microvascular ATBF responses to a meal in 
healthy and T2D subjects, and determine whether these responses are altered by chronic 
exercise training. 
The first aim characterised adipose tissue microvascular blood flow responses in the 
post-prandial state in healthy people. Adipose tissue microvascular blood flow was 
measured by contrast-enhanced ultrasound (CEU) at baseline and 1-hour after a mixed 
meal challenge or an oral glucose challenge (OGC). Adipose tissue microvascular 
blood volume (MBV) and microvascular blood flow (MBF) increased to a similar 
extent with both challenges. This increased microvascular perfusion of adipose tissue 
may improve delivery of key nutrients (e.g. glucose and lipid) from the meal for storage 
in adipose tissue. 
The second aim investigated whether people with T2D have an impairment in adipose 
tissue microvascular responsiveness following an OGC, and whether systemic 
inflammation or the metabolic syndrome is associated with an adipose tissue 
microvascular-linked phenotype. Adipose tissue MBV and MBF post-OGC were 
markedly impaired in T2D when compared to healthy controls. These impaired 
microvascular responses in adipose tissue were associated with obesity, insulin 
resistance, hyperglycaemia and dyslipidaemia, but not systemic inflammation.  
The final aim determined whether chronic exercise training restores adipose tissue 
microvascular blood flow in people with T2D. Adipose tissue microvascular blood flow 
2 
was measured by CEU before and after six-weeks (three days per week) of a fully 
supervised resistance training program. Insulin sensitivity, glycaemic regulation, 
circulating lipids and body composition were all improved in people with T2D 
following resistance training. However, these favourable cardio-metabolic outcomes 
were not associated with a paralleled improvement in adipose tissue MBV and/or MBF. 
Collectively, this thesis has demonstrated that a mixed meal or an OGC induces both 
MBF and MBV increases in adipose tissue in healthy but not people with T2D, and 
these impairments are not restored by six weeks of exercise training. The dissociation 
of impaired adipose microvascular blood flow from inflammation, but association with 
body fat, glycaemic response and lipid handling provides clues about the role of adipose 
tissue microvascular blood flow in metabolic derangements associated with T2D. In 
particular, changes in adipose tissue microvascular blood flow in obesity/T2D may 
affect lipid deposition prior to altering adipose tissue hypoxia and inflammation. 
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Chapter 1: Thesis Introduction 
1.1 Preface 
Type 2 diabetes (T2D) is a chronic disease affecting more than 300 million people 
globally. It is a chronic, progressive disease characterized by elevated levels of blood 
glucose. Long term elevated blood glucose can lead to complications in many parts of 
the body and can increase mortality and morbidity. T2D also causes a large economic 
burden on health-care systems and the global economy. Insulin resistance (IR) is 
suggested to develop as a result of obesity, predisposing to the onset of T2D. Obesity 
is initiated by several factors such as physical inactivity, excess calories and genetic 
predisposition. Obesity is also strongly associated with a state of chronic low-grade 
inflammation in adipose tissue, which may also contribute to IR. Adipose tissue 
expansion (hypertrophy) is thought to result in insufficient blood flow, leading to 
adipocyte hypoxia and the latter is thought to promote inflammation. The current 
management of T2D involves a combination of lifestyle modifications such as exercise, 
reduced energy intake and use of medications designed to lower glycemia. Recently, 
resistance training (RT) has been recommended for T2D management. While benefits 
for glucose control and insulin sensitivity in skeletal muscle have been investigated 
after RT, it is not known whether this involves augmentation of adipose tissue 
microvascular blood flow. Therefore, this project aims to i) characterise adipose tissue 
microvascular blood flow responses in the post-prandial state in healthy subjects, ii) 
investigate whether adipose tissue microvascular responses are reduced in people with 
T2D in the post-prandial state, and iii) determine whether RT alters post-prandial 
adipose tissue microvascular responses in people with T2D. 
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1.2 Obesity and type 2 diabetes  
 
1.2.1 Diabetes mellitus 
 
Diabetes mellitus (DM), which has been linked with a range of health complications, is 
considered a global epidemic in the 21st century [1]. According to the International 
Diabetes Federation, the worldwide prevalence of DM was approximately 415 million 
in 2015 and the number is predicted to increase to 642 million by the year 2040 [2]. 
According to Diabetes Australia, about 1.7 million people in Australia had DM in 2017. 
This includes diagnosed diabetes (1.2 million known and registered) and undiagnosed 
DM (up to 500,000) [3]. In Australia, the annual cost of DM has been estimated at 
approximately $14.6 billion [3]. Also, elevated blood glucose levels over long periods 
of time can lead to dysfunction in both small and large blood vessels [4]. Microvascular 
dysfunction can lead to complications, for example blindness (retinopathy), nerve 
disease (neuropathy) and kidney disease (nephropathy). Macrovascular dysfunction can 
lead to cardiovascular disease (e.g. heart attack) [1, 5]. These vascular complications 
are a major contributor to increased mortality and morbidity, and a large financial 
burden to health-care systems globally [6].  
 
DM is a progressive, chronic metabolic disorder, characterised by long term high blood 
glucose levels, termed hyperglycaemia [1]. DM, including type 1 diabetes (T1D), type 
2 diabetes (T2D) and gestational diabetes for women, are complex metabolic disorders 
that result from defects in insulin secretion, action, or a combination of both [7]. T1D 
makes up approximately 10% of all cases of DM and is caused by an autoimmune 
destruction of the insulin-producing β cells of the pancreas, abolishing insulin section. 
It is still not known what causes this auto-immune reaction [8]. T2D, which often begins 
with insulin resistance (IR), is a condition in which cells fail to respond to insulin 
properly and makes up about 80-90% of cases of DM [9]. Gestational diabetes, which 
is defined as diabetes diagnosed during pregnancy, usually goes away after the baby is 
born but increases the risk of T2D in these women later in life [10].  
 
T2D is a chronic metabolic disorder that is characterized by hyperglycaemia, IR, and 
relative lack of insulin production [1, 11]. According to WHO diabetes diagnostic 
criteria, clinical diagnosis of T2D include: fasting blood glucose level ≥7.0 mmol/L 
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(126mg/dl) (on two separate times) and/or glycated haemoglobin (HbA1c) ≥6.5% (on 
two separate times) and/or 2-hour postprandial blood glucose ≥11.0 mmol/L (200 mg/dl) 
(in response to an oral 75g glucose tolerance test on two separate times). The aetiology 
of T2D is multifactorial, including family history, IR, physical inactivity and obesity, 
but specific mechanisms are not fully understood [12]. However, the development of 
IR is thought to be a universal precursor for developing T2D [13].   
 
1.2.2 Insulin resistance and T2D 
 
IR (observed in pre-diabetic states) precedes the onset of T2D, and plays a pivotal role 
in the development and pathogenesis of T2D [14]. IR often occurs 10 to 15 years prior 
to the development of T2D, and it is accompanied by compensatory hyperinsulinaemia 
[14]. Insulin, which is from the Latin word, insula (meaning island), is a peptide 
hormone secreted from β cells of the pancreatic islets [15]. It has important effects on 
the metabolism of carbohydrates, fats and protein. For example, insulin not only 
reduces blood glucose by improving glucose uptake in skeletal muscle, adipose tissue 
and heart, but it also inhibits glucose production in liver [16] and decreases lipolysis 
[17]. 
 
In order to promote glucose uptake in healthy subjects, insulin causes the movement of 
glucose transporters from intracellular membranes to the cell surface [18]. The insulin 
receptor substrate (IRS) proteins play a key role in insulin signaling. In fact, glucose 
transporter 4 (GLUT4) is highly expressed in adipose tissue and skeletal muscle and it 
is an insulin-responsive member of the glucose transporter family [19]. It is activated 
by binding of insulin to its receptor, which activates its tyrosine kinase activity and 
phosphorylates IRS proteins (particularly IRS-1), in turn activating 
phosphatidylinositol-3-kinase (PI3K) and other downstream effectors [20, 21]. PI3K 
signals through the serine-threonine kinases Akt2 [22, 23] and protein kinase C (PKC) 
isoform λ( PKCλ) [24] to control GLUT4 translocation, leading to glucose transport 
into the cell and stimulation of glycogen synthesis [25]. However, disruption to any part 
of this pathway can result in IR. 
 
IR affects the ability of tissues to respond to insulin which is secreted into the 
circulation in the post-prandial state [26]. During the early stages of IR, insulin 
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produces a less than expected biologic effect and, in turn, reducing whole body glucose 
disposal [27]. The increased postprandial glucose level drives up insulin secretion 
further, leading to hyperinsulinaemia [27]. Consequently, IR results in pancreatic 
“stress”, pancreatic β cell dysfunction and eventually elevated blood glucose levels. 
During the later stages of T2D, the pancreas is not able to produce sufficient amounts 
of insulin and during these circumstances exogenous insulin injection is required to 
manage blood glucose levels [27]. 
IR arises from impaired insulin action in metabolic organs and tissues such as skeletal 
muscle, liver, and adipose tissue [28]. In skeletal muscle, insulin plays an essential role 
in stimulating glucose uptake and metabolism [29, 30]. IR is associated with reduced 
insulin-mediated glucose transport into muscle and muscle glycogen synthesis [30-32]. 
In the liver, IR is characterized by impaired insulin-mediated suppression of 
gluconeogenesis in the fed state [33]. Hepatic IR is also associated with non-alcoholic 
fatty liver disease which is a major risk factor for the development of T2D [34-36]. In 
adipose tissue, IR is manifested as impaired insulin-stimulated glucose transport and 
impaired inhibition of lipolysis [37, 38]. 
1.2.3 Risk factors for developing T2D 
T2D mostly results from the interaction between genetics, physical inactivity and 
elevated central fat. Indeed, T2D has a strong genetic link [39]. People with a family 
history of T2D have a 3 to 4-fold higher risk of developing diabetes than those without 
family history of T2D [40, 41]. In particular, 39% of T2D patients have at least one 
affected parent [42] and the lifetime risk for a first-degree relative of a patient with T2D 
is 5 -10 times higher than that of age- and weight-matched subjects without a family 
history of T2D [43]. This strong family history of the disease suggests the involvement 
of genetic factors for diabetes development. A number of genome wide association 
study (GWAS) have been conducted in diverse populations demonstrating linkage 
signals in chromosomes of people with T2D, and have successfully confirmed about 75 
sensitivity loci correlated to T2D [44]. An example is genes that encode proteins such 
as TCF7L2 (transcription factor 7-like 2, the strongest T2D locus identified to date) that 
cause alterations in several pathways, leading to T2D [45-47]. 
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In addition to genetics, physical inactivity plays a key role in the development of T2D 
[45, 46]. A sedentary lifestyle reduces insulin sensitivity in target tissues (liver, muscle 
and adipose tissue) promoting progression to T2D. In contrast, increased levels of 
physical activity may ameliorate IR by improving insulin action and vascular function 
[45, 47]. Studies have shown that low levels of physical activity are involved in the 
development and progression of IR and T2D [48, 49]. Television watching represents 
a major sedentary lifestyle habit in the United States for example. Adult men spend on 
average about 29 h per week watching television, and adult women 34 h per week [50]. 
Hu and colleagues followed a total of 1,058 participants and examined the relationship 
between television watching time and the incidence of T2D. They found that time spent 
watching television was associated with a significantly higher risk of T2D [51]. 
Television watching is associated with obesity and weight gain, probably because of 
less energy expenditure (i.e., less physical activity) and higher energy intake [50]. 
Higher levels of physical activity are linked to decreased risk factors for developing IR 
and T2D [52] which is at least in part due to weight loss. 
Central obesity is a major risk factor for developing T2D [53]. Not all individuals with 
T2D are obese and many obese individuals do not have diabetes, but the majority of 
T2D individuals have elevated body weight, in particular fat located in the abdominal 
area [54].  
1.2.4 Obesity and type 2 diabetes 
Obesity is defined as a chronic condition caused by excessive fat accumulation resulting 
from an energy imbalance [55]. It can be measured simply using body mass index 
(BMI). It is calculated from the weight-for-height ratio and is widely used for 
classifying overweight and obesity in adults. BMI is defined as: underweight: below 
18.5 kg/m2; healthy weight: 18.5 to 25 kg/m2; overweight: 25 to 30 kg/m2; obese: over 
30 kg/m2 [56]. Overweight and obesity are huge public health challenges worldwide 
now [55]. In 2013, 36.9% of men and 38% of women were overweight/obese adults, 
and 23.8% of boys and 22.6% of girls were children and adolescents [57]. According 
to Australia Obesity Statistics in 2017, 63.4% of Australian adults (11.2 million people) 
are overweight or obese [58]. For middle-aged men the problem is magnified with 75 - 
80% being overweight. Also, 25% of children are classified as overweight in this 
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country. Moreover, there is a strong association between BMI and risk of developing 
T2D [59, 60]. For instance, the prevalence of diabetes increased from 2% in people 
with a BMI of 25 to 29.9 kg/m2, to 8% in people with a BMI of 30 to 34.9 kg/m2, and 
finally to 13% in people with a BMI more than 35 kg/m2 [61]. Each kilogram of weight 
gained annually over a period of 10 years is associated with a 49% increase in risk of 
developing T2D in the subsequent 10 years [11]. In contrast, each kg of weight lost 
annually over 10 years was correlated with a 33% lower risk of diabetes in the 
subsequent 10 years [11]. 
 
 
Although overall obesity confers a significant threat to individual health, central obesity 
has been recognised as an independent higher risk factor for developing metabolic 
disorders and cardiovascular diseases [62, 63]. Indeed, central obesity is a risk factor 
for IR, T2D, hypertension and increased cardiovascular morbidity and mortality [64]. 
Also, central obesity plays a key role in development of IR in various tissues, including 
liver, skeletal muscle and adipose tissue, leading to T2D [65]. How central obesity 
causes IR is not fully understood. However, elevated free fatty acids (FFAs) that are 
released from the expanded adipose tissue are strongly implicated in the development 
of peripheral (skeletal muscle) and hepatic IR [66]. Also, adipose tissue per se can 
develop IR which is characterised by reduced insulin-stimulated glucose disposal and 
impaired lipogenesis which contributes to elevated circulating FFAs.  
 
1.2.5 Obesity and insulin resistance in adipose tissue 
 
It has been suggested that IR and impaired insulin action in adipose tissue occur much 
earlier than glucose intolerance (in fact, a long time before glucose intolerance develops) 
[67]. Adipose tissue consists of adipocytes (cells that store fat), as well as cells of the 
stromal vascular fraction which includes pre-adipocytes (that can differentiate into 
mature adipocytes), vascular smooth muscle and endothelial cells (comprising blood 
vessels) and macrophages [68]. The main role of adipose tissue is to store excess 
calories in the form of triglycerides, and it was thought to be involved only in body lipid 
and energy homeostasis [69]. Recently, it has become more clear that, in addition to 
lipid storage, adipose tissue is an important secretory organ, which produces adipokines 
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and inflammatory cytokines [70]. Disturbances in lipid metabolism (especially FFAs) 
and adipose tissue inflammation might directly contribute to the onset of IR [71].  
 
Indeed, central obese people are characterized by elevated plasma FFA levels. It has 
been established that elevated plasma FFAs play an important role in the pathogenesis 
of IR [72, 73]. With weight gain, FFAs are elevated in obese people and activate protein 
kinases such as PKC, Jun NH2-terminal kinase (JNK), and the inhibitor of nuclear 
factor-κB (NF-κB) kinase-β (IKKβ) in a number of tissues. This can lead to insulin 
signalling being impaired by these kinases, via an increase in the inhibitory serine 
phosphorylation of IRS (a key mediators of insulin receptor signalling), leading to IR 
[74]. Studies showed that acute elevations of plasma FFA levels (by intravenous 
infusion of heparinized lipid emulsions) lead to IR [66, 75]. The FFA-induced IR 
developed after 2 hours and disappeared about 4 hours after normalization of plasma 
FFA. This effect was dose dependent IR [66, 75]. Chronically elevated plasma FFA 
levels are also strongly implicated in the development of IR. Santomauro and 
colleagues have shown that acipimox (250 mg) (a long-acting nicotinic acid analogue 
that lowers plasma FFA levels by inhibiting lipolysis) decreased fasting plasma FFA 
concentrations (by 60-70%) and plasma insulin (by about 50%) in lean and obese 
people. This suggests that lowering plasma FFA concentrations can decrease 
IR/hyperinsulinaemia and improve oral glucose tolerance in lean and obese people with 
and without T2D [76]. 
 
Obese conditions are also often associated with a state of low-grade chronic 
inflammation. Adipose tissue expansion is thought to result in insufficient blood flow 
and hypoxia to the adipocyte, triggering production of inflammatory cytokines, which 
affect insulin signaling, resulting in IR [77]. During the last several decades, 
experimental, epidemiological, and clinical studies have shown causal links between 
inflammation and the development of IR and T2D [78, 79]. Activation of inflammatory 
pathways in hepatocytes might induce both local [80] as well as systemic IR [81]. The 
role of inflammatory markers in development of IR is further detailed in section 1.3. 
 
1.2.6 Raised plasma FFAs causes insulin resistance 
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The usual cause of obesity is an inbalance between energy intake and output. Generally, 
lipids are stored as triglycerides in adipose tissue (e.g. after meal ingestion) and to 
release FFAs for utilization by oxidative tissues (e.g. skeletal muscle, heart, and liver) 
in times of energy demand (e.g. fasting, exercise) [82]. Adipose tissue may occupy 50 % 
of the whole-body weight in an adult, and this tissue can provide more than 85% of the 
total stored energy [83]. However, when adipose tissue cannot meet the demand for 
storing excessive energy, triglycerides are accumulated as ectopic fat (defined by excess 
adipose tissue in sites not classically in adipose tissue storage) and excessive FFAs are 
released into the circulation which also impair insulin signalling in muscle and the liver, 
leading to IR [84, 85].    
 
Plasma FFA levels are about three-fold higher in abdominally obese adults when 
compared to non-obese adults [86, 87]. Skeletal muscle accounts for about 80 % of 
postprandial insulin-stimulated glucose disposal. However, skeletal muscle is also a 
major site of FFA utilization [88, 89]. Studies in obese humans and high fat-fed rats 
have revealed an enhanced transport of FFAs into skeletal muscle which is associated 
with an increased intramyocellular triglycerides content [90, 91]. FFAs in skeletal 
muscle are stored in the form of intramyocellular triacylglycerol and represent an 
important source of energy [92]. However, excessive accumulation of FFAs suppress 
insulin-stimulated glucose uptake at the level of glucose transport and/or 
phosphorylation [93, 94]. The possible mechanism is that elevated intramyocellular 
diacylglycerol and long-chain acyl-CoA, activate PKC, and decrease tyrosine 
phosphorylation of IRS-1, and this is thought to be central to the pathogenesis of IR-
associated diseases such as T2D [35, 92, 95]. Also, elevated intramyocellular lipids in 
skeletal muscle have been demonstrated to activate PKC and the IκB kinase (IKK)/NF-
κB signaling pathways, which affect downstream action of the insulin signaling 
pathway, leading to IR [17]. For the liver, increasing hepatic FFAs flux, which increase 
hepatic glucose production, have been thought as a main driving force for systemic IR 
[96, 97]. Studies have shown that higher FFAs cause hepatic IR, lead to hepatic 
accumulation of diacylglycerol and activate two serine/ threonine kinases (PKC-δ and 
IKK-β), which play a key role in developing T2D [96-98]. 
 
The transport of triglycerides and FFAs to and out of the tissue involves specialized 
transport mechanisms including delivery and removal from adipose tissue by the 
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vasculature [99]. Increased postprandial plasma triglyceride and FFA is associated with 
reduced adipose tissue blood flow (ATBF) [100]. ATBF has been suggest to impact on 
lipid clearance [101]. This suggests that ATBF potentially plays an important role in 
lipid metabolism [83]. ATBF will be discussed more detail later. 
 
1.3 Inflammation in adipose tissue 
 
1.3.1 Inflammation and obesity 
 
Inflammation is a physiological reaction necessary to restore homeostasis and 
characteristics of inflammation are raised numerous white blood cells or elevated levels 
of pro-inflammatory cytokines in the circulation or in tissue [102]. In general, 
inflammation is required for organ remodelling, tissue repair, wound healing and 
immunity against infections [16]. However, in overweight and obese individuals, 
adipose tissue releases inflammatory cytokines, which are associated with the 
pathogenesis of a number of chronic diseases, such as IR, cardiovascular disease and 
T2D [103].  
 
In insulin sensitive individuals, adipose tissue has capacity to increase its size 
dramatically [104]. Sufficient oxygen supply plays a determinant role in maintaining 
normal adipose tissue function [105]. During obesity, adipose tissue expansion can 
occur in two ways, via hypertrophy (increase in adipocyte size) or via hyperplasia 
(increase in adipocyte number), with the former being more metabolically detrimental 
[106]. This is in part due to the adipocyte increasing in cell size while there is a 
concomitant decrease in microvascular density, which may limit oxygen supply, 
leading to hypoxia [107, 108]. Local tissue hypoxia may occur at the early stages of 
adipose tissue expansion and limit normal adipose tissue function [84]. In this hypoxic 
environment, macrophages are activated to release inflammatory cytokines [109, 110]. 
Studies have suggested that the oxygen partial pressure in adipose tissue is low during 
obesity in both humans and animals [111-115] and may be an important link to hypoxia-
driven chronic inflammation in obesity [111]. 
 
Moreover, due to adipose tissue expansion, adipose tissue becomes dysfunctional [116]. 
During obesity, when adipose tissue becomes dysfunctional it can lead to exaggerated 
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release of FFAs and pro-inflammatory cytokines leading to ectopic lipid deposition, 
which together contribute to IR and T2D [117] . In one study, three months of high fat 
feeding of mice caused low grade hepatic inflammation [118]. This showed that the 
inflammatory state was linked to the high fat diet. FFA may be one of candidates 
because FFA and inflammation are both elevated in most obese subjects in the post-
prandial state [119, 120] . In addition, acutely raised plasma FFA not only resulted in 
peripheral and hepatic IR, but also activated the pro-inflammatory NF-κB pathway, 
leading to increased production of pro-inflammatory cytokines [97, 121]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Summary of inflammatory cytokines develop during the obese status: 
adipose tissue hypertrophy, macrophage infiltration and changed adipokine secretion. 
During weight gain, adipose cell increases its size, which leads to adipose tissue 
hypertrophy, macrophage infiltration and high levels of pro-inflammatory markers.  
 
1.3.2 Inflammation and insulin resistance 
 
Adipose tissue is a highly dynamic endocrine organ, secreting a large number of 
adipokines such as leptin, adiponectin and inflammatory cytokines [122-124]. 
Inflammatory cytokines play a key role in the development of IR via various molecular 
pathways [125, 126]. As discussed above, during obesity it is thought that as the 
adipocyte undergoes hypertrophy, insufficient microvascular blood supply to the 
adipocyte leads to hypoxia, macrophage recruitment and conversion of macrophages 
from an inactive state (M2) to an active state (M1) in which they are reported to release 
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tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin-1 beta (IL-1β) 
and monocyte chemoattractant protein-1 (MCP-1) [85, 127, 128] (Figure 1.1). 
Moreover, TNF-α, IL-1β, IL-6, C-reactive protein (CRP), MCP-1 and soluble vascular 
cell adhesion molecule-1(sVCAM-1) are possibility associated with obesity or T2D 
[129-135].  
 
Adipose tissue inflammation may contribute to whole-body IR and T2D via the 
endocrine effects of inflammatory cytokines secreted by adipose tissue on insulin 
sensitivity in various tissues, particularly in skeletal muscle and liver [125, 126]. Six 
inflammatory markers have been found to be associated with IR. As discussed below, 
there are several pathways of how inflammatory markers may be coupled to impaired 
insulin signalling in adipocytes, leading to IR and T2D (Figure 1.2). 
 
1.3.3 Tumour necrosis factor alpha (TNF-α) 
 
TNF-α is a pro-inflammatory cytokine produced by various cell types such as adipose 
cells, although predominantly by macrophages and lymphocytes [136]. The primary 
role of TNF-α is in the regulation of immune cells and make up the acute phase reaction 
[137]. TNF-α increases have been identified in adipose tissue and increased during 
obesity and it has been shown to interfere with insulin signalling [138]. Mice lacking 
TNF-α are protected from obesity-induced IR [139]. Hotamisligil and colleagues have 
shown that increased TNF-α expression in adipose tissue of obese humans is correlated 
with the degree of hyperinsulinaemia, while TNF-α expression is decreased with weight 
loss, suggesting a potential mechanistic role in human obesity-induced IR [140]. It has 
been suggested that TNF-α inhibits insulin signal transduction and it may also decrease 
insulin secretion [141]. Studies have shown that TNF-α impairs skeletal muscle insulin 
signalling and reduces whole body glucose uptake in healthy animals and humans [142, 
143]. TNF-α also causes an increase in FFA release by adipocytes, leading to increased 
levels of circulating FFAs, which can reduce insulin signalling in other tissues [144].  
 
TNF-α is an adipose tissue-derived pro-inflammatory cytokine that causes IR by 
improving adipocyte lipolysis and enhancing the serine/threonine phosphorylation of 
IRS-1[67, 79]. Actually, TNF-α triggers a broad spectrum signaling cascade that results 
in the activation of various transcriptional pathways such as NF-κB and JNK [145, 146]. 
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Once NF-κB and JNK are activated, they phosphorylate serine 307 in IRS-1 which 
results in the impairment of IR-mediated tyrosine phosphorylation of IRS-1 [145]. 
 
 
1.3.4 Interleukin-1 beta (IL-1β) 
 
IL-1β plays a key role in regulating the body’s inflammatory response and it is produced 
during infection, injury, and antigenic challenge [147]. The macrophage produces most 
of the IL-1β in the body, but epidermal, epithelial, lymphoid and vascular tissues also 
synthesize IL-1β [148-150]. Mandrup-Poulsen and colleagues demonstrated that IL-1β 
impaired β-cell function [151, 152]. In addition to impaired β-cell function, IL-1β was 
suggested to cause β-cell death, which was potentiated by the cytokines such as 
interferon-γ (IFN-γ) and TNF-α [153, 154]. The possible mechanism is that IL-1β 
principally affects the activation of mitogen-activated protein kinases (MAPK) and NF-
κB on expression of the encoding gene in the process of β-cells death [148, 155]. 
 
IL-1β expression is highly upregulated in pancreatic islets of patients with T2D [156-
158]. It plays a key role in developing IR by attenuating insulin signalling in peripheral 
tissues and macrophages, resulting in insulin sensitivity reduction of β-cells and 
possibly impaired pancreas action [159, 160]. IL-1β was shown to dramatically increase 
suppressor of cytokine signalling - 3 (SOCS-3) protein expression, which can impair 
insulin signalling by binding to the insulin receptors and suppress their capacity to 
phosphorylate IRS proteins [161]. Moreover, SOCS proteins are able to bind directly 
to IRS proteins, which results in IRS degradation [162, 163]. Indeed, it has been 
suggested that IL-1β decreased insulin-stimulated glucose transport in adipocytes 
primarily by supressing IRS-1 levels expression via a reducing IRS-1 mRNA [164]. 
 
1.3.5 Interleukin 6 (IL-6) 
 
IL-6 is secreted by multiple tissues such as skeletal muscle and liver, and particularly 
in adipose tissue, which secretes about 30% of IL-6 in healthy individuals [125, 165]. 
The major function of IL-6 is to activate immune response during infection and after 
trauma, particularly burns or other tissue damage, resulting in inflammation [166]. IL-
6 is implicated as a predictor or pathogenic mediator of cardiovascular disease and IR 
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[167, 168]. IL-6 secretion is increased in obese subjects and may contribute to 
regulation of insulin action [169]. IL-6 is suggested to be a typical pro-inflammatory 
cytokine because its expression is enhanced in adipose tissue during weight gain, 
especially from the visceral depot [170]. Abdominal adipose tissue produces 3-fold 
higher IL-6 than subcutaneous adipose tissue, suggesting that IL-6 produced by 
abdominal adipose tissue is a potential factor for developing of IR [171]. Also, plasma 
IL-6 levels are elevated in people with T2D, particularly in those with features of insulin 
resistance syndrome and the elevated circulating level of IL-6 is an independent 
predictor of T2D [155, 172]. 
 
IL-6 is recognized as causing IR by decreasing the expression of GLUT-4 and IRS-1 
[125]. Also, these effects are influenced by the stimulation of the Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) signalling pathway and enhanced 
the expression of SOCS family (e.g. SOCS-3), inhibiting insulin receptor signal 
transduction[173]. Interestingly, IL-6 has been suggested to be an interleukin that acts 
as both a pro-inflammatory cytokine and an anti- inflammatory cytokine [174, 175]. 
Indeed, there are a number of studies showing that IL-6 has anti-inflammatory effects 
[176] and that it may even play an important role in improving insulin sensitivity in 
skeletal muscle [177]. Regarding IL-6, the pro- versus anti- inflammatory properties of 
IL-6 are context dependent (acute versus chronic, skeletal muscle or adipose tissue 
origin) [174]. Studies have shown that IL-6 levels increased after acute exercise and 
during exercise [178, 179]. Also, acute IL-6 treatment enhances insulin sensitivity in 
humans [177]. 
 
1.3.6 C-reactive protein (CRP) 
 
CRP is synthesized by the liver and is induced by pro-inflammatory cytokines including 
IL-6 and TNF-α [180, 181]. The main function of CRP is in the innate immune system 
and it is the first acute-phase protein to be described. It is a sensitive systemic indicator 
of inflammation and tissue damage [182, 183]. Moreover, increased CRP levels have 
been associated with endothelial dysfunction and vascular inflammation [184]. It has 
been suggested that high circulating levels of CRP are a marker for cardiovascular 
disease risk and circulating CRP has also been significantly correlated with IR [183, 
185-187].  
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In most human studies, CRP is detected by using high-sensitivity assays and is 
identified as high-sensitivity CRP (hs-CRP)[188]. Studies have shown that elevated 
serum hs-CRP was dose-dependently associated with an increased degree of IR [187, 
189, 190]. Hs-CRP may cause IR by causing IRS-1 phosphorylation at Ser307 and 
Ser612 through JNK and ERK1/2, respectively, resulting in impaired insulin-induced 
glucose uptake, GLUT4 translocation, and glycogen synthesis by the IRS-1/PI-
3K/Akt/GSK-3 pathway [191, 192]. Many studies have demonstrated that people with 
elevated levels of CRP have a high risk of T2D [193, 194]. For example, a recent study 
showed that one-third of T2D cases are associated with elevated serum CRP [195]. 
However, a meta-analysis has suggested that hs-CRP may not always be an independent 
risk factor for developing T2D [196]. 
 
1.3.7 Monocyte chemoattractant protein-1 (MCP-1)  
 
MCP-1 (also called CCL2) is a pro-inflammatory chemokine produced by adipocytes, 
macrophages, smooth muscle, and endothelial cells [79, 197]. MCP-1 is a member of 
the C-C chemokine family and plays a key role in regulating migration and infiltration 
of monocytes/macrophages [198]. MCP-1 is associated with various diseases such as 
multiple sclerosis[199], rheumatoid arthritis [200], atherosclerosis [201], IR and T2D 
[202]. MCP-1 attracts monocytes to the inflammatory area of vascular endothelial space, 
which causes atherogenesis in large arteries and obesity-stimulated macrophage 
infiltration in fat tissue [203].  
 
Adipose tissue macrophage infiltration is close linked with IR and vascular endothelial 
dysfunction in obese individuals [204]. The expression of MCP-1increases during 
obesity, especially in visceral fat areas, and might play an important role in developing 
IR, particularly in the liver [197, 205]. Studies have shown that MCP-1 is overexpressed 
in diet-induced IR and obese mice (ob/ob and db/db mice) compared with their lean 
controls, MCP-1 might contribute to the development of IR in adipose tissue and cause 
adipocyte de-differentiation [197, 202, 206]. Also, MCP-1 overexpression by adipose 
cells leads to hepatic steatosis and IR in liver, muscle and adipose tissue [197, 202, 206]. 
Moreover, circulating MCP-1 was significantly increased in people with IR status or 
T2D [207-209]. It has been shown that MCP-1, via activation of extracellular signal 
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regulated kinase (ERK) 1/2 pathways, and causes an increase in the expression of 
amylin in pancreatic β cells and IR, promoting development of T2D [210, 211]. 
 
1.3.8 Soluble vascular cell adhesion molecule-1 (sVCAM-1) 
 
VCAM-1 is expressed mainly by endothelial cells, smooth muscle cells, and tissue 
macrophages [212, 213]. Soluble forms (sVCAM-1) have been identified in plasma 
[214]. VCAM-1 expression is increased by several inflammatory molecules like TNF-
α and IL-1 [215]. sVCAM-1 plays a key role in accelerating atherosclerosis by 
facilitating the attachment of inflammatory cells to the vascular endothelial wall and 
promoting their subsequent migration through the endothelium [216]. The resulting 
inflammatory response, injury, and stiffening of the vascular wall may result in 
impaired blood flow regulation in organs and tissues [216].  
 
Increased plasma concentrations of sVCAM-1 are found with increasing adiposity, 
which demonstrated that increased adipose tissue mass may be correlated with 
increased endothelial activation [217]. VCAM-1, which is released from adipose cells, 
may play an important role in recruiting immune cells into adipose tissue [218]. 
Elevated concentrations of sVCAM-1 is also linked to dyslipidaemia, cardiovascular 
disease, IR and T2D [135, 219-222]. Indeed, epidemiological studies have shown that 
elevated sVCAM-1 levels signify endothelial dysfunction and independently predict 
the risk of future T2D [223-225]. Although the molecular mechanisms for the 
relationship between sVCAM-1 and T2D are unclear, it has been postulated that 
endothelial dysfunction induced by sVCAM-1 may lead to IR and thereby facilitate 
progression to T2D [226, 227]. 
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Figure 1.2: Summary of inflammatory pathways linking inflammation to insulin 
resistance and T2D. NF-κB: nuclear factor κB; JNK: Jun NH2-terminal kinase; SCOS3: 
suppressor of cytokine signaling-3; JAK-STAT: Janus kinase-signal transducer and 
activator of transcription; GLUT-4: glucose transporter-4; ERK1/2: extracellular 
signalregulated kinase 1/2; IRS-1/2: insulin receptor substrate-1/2; PI-3K: 
phosphatidylinositol-3-kinase. 
 
1.4 ATBF  
 
1.4.1 ATBF and function 
 
As mentioned above, adipose tissue expansion may result in adipocyte hypertrophy and 
hypoxia, which contribute to the adipose tissue dysfunction and a pro-inflammatory 
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state [77, 228]. However, as the main function of ATBF is to regulate metabolic 
homoeostasis, adipose tissue is highly vascularised [229]. ATBF is able to regulate to 
store and remove lipids when needed such as during stress, exercise and fasting [230]. 
Adipose tissue controls its metabolism in part by regulating its blood flow [99, 231]. 
This is because blood flow delivers key nutrients (e.g. oxygen and glucose) and 
hormones (e.g. insulin) and removes waste products for individual tissues [232]. ATBF 
is highly dependent on nutritional status, increasing significantly postprandially in 
healthy individuals [233-236].  
 
However, ATBF is impaired in obese or IR individuals [122, 234, 235, 237, 238]. In 
adipose tissue, microvascular blood volume (MBV) and microvascular blood flow 
(MBF) have been shown to be impaired in IR mice [122]. Belcik, et al. performed 
abdominal adipose tissue perfusion imaging in obese IR (db/db) mice at 11-12, 14-16 
weeks of age, and control lean mice. They found Db/db mice not only had higher fasting 
blood glucose and glucose area-under the curve (AUC), but also had lower adipose 
MBF and MBV (represents the numbers of capillaries open in adipose tissue). Also, the 
glucose AUC was positively correlated with adipose tissue MBF (r = 0.81) and MBV 
(r = 0.66) [122]. Recently, high-fat diet fed rats were demonstrated to have impaired 
capillarization and postprandial blood flow in adipose tissue and demonstrated that such 
events were associated with lower insulin sensitivity [238].  
 
Adipose tissue MBF is impaired at baseline and postprandially in obese or IR status 
subjects [234, 235, 237]. For example, ATBF was impaired in the obese subjects, 
compared with the age-matched non-obese (P < 0.05) [237]. Frayn and colleagues have 
shown that the postprandial ATBF response is attenuated in obesity [234, 235, 239]. 
They also suggested that impaired regulation of postprandial ATBF is another facet of 
the insulin resistance syndrome [234]. Moreover, microvascular dysfunction is 
associated with decreased insulin sensitivity [240] and postprandial ATBF is 
significantly positively with insulin sensitivity [234, 241].  
 
1.4.2 Regulators of ATBF 
 
ATBF is very labile [242] and there are several factors that regulate ATBF (Table 1.1). 
After an overnight fast, the abdominal subcutaneous ATBF is typically about 3-5 mL 
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blood per 100 g adipose tissue per minute, while it is about 1.5 mL in skeletal muscle 
[243]. Interestingly, adipose tissue increases blood flow at night [244]. A 14 h -22 h 
fast does not change blood flow [245], but 72 h fasting improves the blood flow to 
adipose tissue to approximately 1.5 fold [246]. 
 
Moreover, ATBF increases up to four-fold in response to a meal in healthy people [233-
235]. Also, ATBF reaches a peak at about 30 minutes following a mixed meal [235]. 
When glucose loading or a mixed meal was given to participants, the ATBF of healthy 
people was gradually increased several fold and then decreased to the baseline [100, 
234, 235]. Introduction of NG-monomethyl-l-arginine (L-NMMA), which is a blocker 
of nitric oxide (NO) synthesis, reduced fasting ATBF by 30 - 50%, suggesting that the 
endothelial NO system at least in part contributes to normal ATBF homeostasis [247, 
248]. However, as mentioned above, this increase in ATBF induced by meals is 
impaired by obesity or IR [122, 234, 235, 237, 238]. 
 
Compared with skeletal muscle blood flow which can increase blood flow by 20-fold 
in response to exercise [242], ATBF increases up to around two-fold during exercise in 
healthy participants [249-252]. Interestingly, a small but significant increase in ATBF 
was observed during exercise in people with T2D [250]. The blood flow immediately 
dropped back to baseline levels after 60 minutes exercise and remained at this level for 
the remaining of the study [250]. However, ATBF in young, healthy subjects is much 
higher than that in people with T2D during and after exercise [249, 253]. 
 
Adrenaline is another important regulator of ATBF, as it exerts effects on both 
adipocytes and the vascular bed by acting through α1- and α2 – adrenoceptors, and β1- 
and β2-adrenoceptors (promoting vasoconstriction and inhibition of lipolysis) [254]. In 
humans, β-adrenergic stimulation significantly increases ATBF following β-adrenergic 
infusion or local delivery of β-adrenaline [255, 256]. However, previous reports have 
shown that α-adrenergic stimuli has an inhibitory effect on fasting ATBF [257, 258]. 
Ardilouze and colleagues illustrated that NO mainly regulates fasting ATBF and to 
some extent α-adrenergic system controls ATBF and β - adrenergic system principally 
regulates ATBF during postprandial status [247]. 
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Table 1.1: Factors that regulate ATBF. ↑ Increase; ↓ Decrease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3 Methods for measuring ATBF 
 
There are several methods for determining ATBF described in previous studies. Most 
of these techniques are suitable for measuring subcutaneous adipose tissue perfusion, 
whereas visceral adipose tissue perfusion can only be measured by means of positron 
emission tomography (PET) [237].  
 
PET is one of methods for measuring ATBF in humans [237, 251, 259]. In a PET scan, 
radioisotopic water [15O]-H2O is used as a positron-emitting tracer to measure blood 
flow in adipose tissue [237, 251, 259]. Before the PET experiments, the antecubital vein 
is cannulated for tracer administration [251]. The fractional rate of tracer uptake is 
quantified by using graphical analysis of subcutaneous adipose tissue and visceral 
adipose tissue time-activity curves in 3D mode [259]. However, disadvantage of PET 
in a clinical research is the high cost [260]. 
 
Laser Doppler flowmetry (LDF), which uses laser light to monitor the movement of red 
blood cells, is a non-invasive tool to investigate blood flow changes in subcutaneous 
adipose tissue of people [261, 262]. The principle of LDF is that a fiber-optic probe is 
Factors Type of regulation References 
Fasting ↑ [242], [243], [244] 
Meals ↑ [100], [231], [232], [233] 
NG-monomethyl-l-
arginine ↓ [245], [246] 
Obesity ↓ [233], [235] 
Insulin resistance ↓ [122], [236] 
Exercise ↑ [247], [248], [249], [250], [251] 
α- adrenergic stimulation  ↓ [255], [256] 
β - adrenergic stimulation  ↑ [253], [254] 
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attached to or inserted into the investigated tissue such as subcutaneous adipose tissue, 
and the Doppler shift of laser light occurs during light scattering by moving red blood 
cells. The amount and velocity of the blood flow in subcutaneous adipose tissue are 
measured by analysing the periodicity content of the backscattered light [261]. The LDF 
technique is easily performed and minimally invasive and has an excellent time 
resolution [261]. However, LDF has disadvantages as the signal is often collected 
superficially, so it can be difficult to determine the influence of skin blood flow on 
measurements [99]. 
 
Microdialysis using small molecules such as ethanol has been used to measure small 
changes of blood flow in adipose tissue [263-266]. Microdialysis probes are inserted 
percutaneously into the subcutaneous adipose tissue, and when ethanol is included in 
the perfusion solution, the ethanol clearance from the probe is a measure of tissue blood 
flow [263-265]. However, microdialysis is not able to measure rapid changes in blood 
flow, while limits the usefulness of this technique [266-268]. 
 
The 133Xe-washout technique for determining ATBF has been the most widely applied 
since its introduction in 1966 [269]. The technique is based on the principle that the 
clearance of a substance injected into a tissue depends on blood flow through the tissue 
[270, 271]. Frayn and colleagues have developed and used this method to measure 
ATBF in people [229, 234, 235, 247, 272]. Using this technique, they have 
demonstrated that total ATBF increases: (i) post-prandially [235]; (ii) in response to an 
oral glucose challenge [247]; and (iii) during insulin infusion (euglycemic 
hyperinsulinemic clamp) [273]. Notably, since 133Xe is highly lipid soluble, having a 
high distribution coefficient, it allows extended examination on the same area. 
 
Recently, contrast-enhanced ultrasound (CEU) has been developed to measure ATBF 
in animals and humans [122, 274-276]. This was made possible in part with the 
development of the CEU technique for skeletal muscle [276-279]. Over the past 15 
years the importance of microvascular blood flow in skeletal muscle for insulin action 
has been demonstrated by using CEU [296-302]. Briefly, a transducer interfaced with 
an ultrasound system is placed on the subcutaneous adipose tissue depot right of the 
umbilicus. Microbubbles (contrast agent) are continuously infused intravenously for 
imaging. Once the microbubble levels have reached steady-state (5 min) in the whole 
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body, a high energy destructive pulse of ultrasound is transmitted to destroy 
microbubbles within the volume of adipose tissue being imaged. Digital image analysis 
of the reflow of microbubbles into the tissues is performed off-line to calculate MBF 
rates [276]. The advantage of CEU over other techniques is the capacity to measure 
blood flow in the microvasculature (rather than bulk blood flow) and to isolate the 
microvascular responses − in particular, MBV, velocity and MBF [280, 281]. 
 
Indeed, the CEU technique has the capacity to isolate the measurement to the 
microcirculation and dissect different perfusion components – in particular, MBV 
(representing the number of capillaries being perfused), microvascular flow velocity ( 
– the filling rate of the capillaries being perfused) and MBF (which is the product of 
MBV and ) [280, 281]. This technique has recently been used to demonstrate that 
MBV in adipose tissue increases (microvascular recruitment) in response to an oral 
glucose tolerance test [274], and insulin infusion (euglycemic hyperinsulinemic clamp 
or intraperitoneal insulin injection) [116, 122, 274, 276]. 
 
 
1.5 Management of T2D 
 
Lifestyle modifications and metformin monotherapy are recommended as the first steps 
to treat T2D [282, 283]. The major goal of this treatment is to control blood glucose 
levels and HbA1C within the normal range [282, 283]. However, most people with T2D 
will eventually require further treatment with more than one anti-diabetic drug to 
maintain their glycaemic goals, because T2D is a progressive condition [284]. Indeed, 
many people with T2D on monotherapy will not be able to maintain glycaemic control 
after just a few years and additional drugs will have to be introduced [285]. Moreover, 
combination of two or more pharmacological agents for managing T2D is often still 
unable to restore normoglycaemia over the long term [286]. In addition, the current 
treatment medication options often have negative side effects, such as body weight gain, 
hypoglycaemia and increased risk of cardiovascular diseases [286, 287]. Therefore, 
there is an urgent need to develop new treatment strategies to combat the increasing 
incidence of T2D.  
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1.5.1 Exercise and resistance training  
 
Exercise is typically one of the first treatment strategies to combat obesity and T2D and 
to improve insulin sensitivity and reduce obesity-induced chronic inflammation [288, 
289].  The American Diabetes Association (ADA) and the American College of Sports 
Medicine (ACSM) have exercise guidelines for the prevention and treatment of T2D 
based on multiple large randomized controlled trials [290, 291]. Also, the Australian 
National Heart Foundation (NHF) has suggested that all people with T2D should 
undertake 30 minutes or more of moderate exercise on most or all days of the week 
[292]. Regular chronic exercise has been illustrated to improve glucose tolerance, 
insulin sensitivity and lipid profiles [293-296]. Elevated HbA1c levels are predictive of 
vascular complications in T2D people, and regular exercise has been shown to reduce 
HbA1c levels, both alone and in conjunction with dietary intervention [289].  
 
Moreover, regular long-term exercise has been shown to promote healthier skeletal 
muscle, liver, adipose tissue and pancreas function [289] (Figure 1.3). For example, 
regular exercise enhances skeletal muscle glucose uptake [297], and results in sustained 
improvements in insulin sensitivity and glucose disposal [298], and improves 
microvascular blood flow in skeletal muscle [299]. As with skeletal muscle, IR is also 
present in the liver in subjects with T2D, but exercise training intervention has been 
suggested to reduce hepatic IR, improve glucose uptake and insulin sensitivity [300, 
301]. Also, exercise training provides numerous positive effects on adipose tissue, for 
example fat mass reduction, insulin sensitivity improvement, and reduced levels of 
inflammation [302, 303].  
 
However, the relationship between exercise and inflammatory cytokine levels is 
complicated. During acute exercise, IL-6 is released from the contracting skeletal 
muscle cells into the blood [304]. As IL-6 has been considered a classic pro-
inflammatory cytokine, the first possible explanation is that the IL-6 response was 
related to muscle damage. Also, IL-6 has been suggested to be an interleukin that works 
as both a pro-inflammatory cytokine and an anti- inflammatory cytokine [174, 175], so 
elevated IL-6 induces a subsequent increase in the production of IL-1 receptor 
antagonist (IL-1ra) and IL-10 by blood mononuclear cells, thus stimulating the 
occurrence of anti-inflammatory cytokines [305]. This is because IL-1ra inhibits IL-1β 
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signal transduction [305], and IL-10 is suggested to inhibit synthesis of pro-
inflammatory cytokines such as TNF-a [175]. Indeed, an experimental study has 
confirmed that increased IL-6 acts to inhibit the production of TNF-α during physical 
exercise [306].  
 
Regular exercise has been suggested to reduce pro-inflammatory markers such as TNF-
α, IL-6, CRP and MCP-1. For example, a combined diet and exercise intervention 
suggested that TNF-α, IL-6, CRP and MCP-1 in adipose tissue of obese people 
significantly decreased after 15-week exercise training [307]. Interestingly, sVCAM-1 
levels were significantly decreased after 15 weeks of low volume high intensity swim 
training [308]. However, other work has suggested that inflammation e.g. TNF-α, IL-
1β, IL-6, CRP and MCP-1 does not change after exercise training [133, 309-312]. 
Exercise training had no effect on inflammation such as TNF-α and IL-6 in subjects 
with T2D exposed to a 12 week intervention period after a one year follow up [312]. 
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Figure 1.3: Benefits of exercise training on specific tissue in people with type 2 
diabetes.  
 
Recently, resistance training (RT) has gained considerable recognition as a viable 
exercise training option for subjects with T2D [313]. RT is an exercise that increases 
muscle strength through an external resistance or own body weight with the expectation 
of increases in strength, tone, mass, and/or endurance [314]. A RT program has also 
been recommended for people with T2D by the American Diabetes Association (ADA) 
and the American College of Sports Medicine (ACSM) [315, 316]. These two 
organizations recognize the positive effects of RT and recommend it no less than twice 
per week for people with T2D [317]. A randomized controlled trial has suggested that 
RT is able to improve glycaemic control in people with T2D, enhance glucose disposal, 
and even improve the lipid profile and reduce cardiovascular system disease risk for 
people with T2D [318, 319]. Also, RT is able to improve insulin sensitivity through 
enhancing the amount of GLUT4 protein, improving total muscle mass and increasing 
the number of insulin receptors on myocytes [320].  
 
 
EXERCISE
Adipose
Inflammation ↓
Fat mass ↓
Insulin sensitivity↓ 
Muscle
Glucose uptake ↓
Glucose and fatty acid 
oxidation ↓
Insulin sensitivity↓ 
Liver
Insulin sensitivity↓
Hepatic glucose production ↓
Triglyceride accumulation ↓
Circulatory
Blood glucose, HbAc1↓
Triglycerides and FFAs ↓
Blood pressure ↓
Pancreas
Insulin ↓
Glucagon ↓
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Moreover, RT has been found to increase skeletal muscle blood flow in humans [321-
323]. Studies suggest that the ATBF increases in healthy humans during and after acute 
exercise [249, 251, 324, 325]. Also, acute exercise has been shown to improve ATBF 
in obese children [326]. There are very few studies that have investigated the effects of 
chronic exercise interventions on human ATBF. To date, most studies on human ATBF, 
such as those of Frayn and colleagues [99, 101, 272] have used 133Xenon washout which 
measures the disappearance of the isotope injected into adipose tissue where faster 
disappearance reflects higher blood flow in adipose tissue. Using this technique it has 
been reported that ATBF is higher in trained versus sedentary healthy individuals [327, 
328]. Sixteen weeks of endurance exercise training in young healthy lean men improves 
aerobic capacity by ~25%, but does not improve body composition (fat mass or lean 
muscle mass) or resting or epinephrine stimulated ATBF [329]. Similarly, 12 weeks of 
aerobic exercise training in healthy older women produced a significant increase in 
exercise capacity, but again, this improvement was not associated with changes in body 
composition or resting ATBF [330]. There have also been mixed findings regarding the 
impact of chronic exercise training (12-16 weeks) on ATBF in overweigh/obese 
individuals when assessed indirectly using microdialysis [331, 332]. Others have shown 
that RT intervention can reverse microvascular impairments in skeletal muscle and 
improve metabolic function of people with T2D [299]. However, the effect of RT on 
ATBF of people with T2D is still unknown.  
 
1.6 Aims and hypotheses 
 
Microvascular blood flow is important for delivery of key nutrients (e.g. oxygen, lipids 
and glucose) and hormones (e.g. insulin) to and removal of waste products from adipose 
tissue. Total ATBF increases after a meal, and this response is impaired in obesity and 
T2D. Microvascular blood flow is more important than total blood flow for nutrient 
exchange in many tissues, however it is not known whether microvascular blood flow 
in adipose tissue is altered by meals or T2D. Chronic exercise training improves 
microvascular blood flow in skeletal muscle of people with T2D. Whether adipose 
tissue microvascular responses are similarly improved following exercise training in 
people with T2D is unknown. The overarching goal of the current thesis is to 
characterise microvascular ATBF responses to a meal in healthy and T2D subjects, and 
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determine whether these responses are altered by chronic exercise training. Figure 1.4 
describes the overarching current project’s hypothesis and aims.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Summary of hypothesis and the aims of the current project.  
 
Aims and hypotheses of project 
 
Hypothesis 1: 
Adipose tissue microvascular blood flow increases in the post-prandial state in healthy 
people. 
Aim 1: 
To characterise post-prandial adipose tissue microvascular blood flow responses in 
healthy subjects (Study 1, 2). 
 
Hypothesis 2: 
People with T2D have impaired post-prandial adipose tissue microvascular responses.   
Aim 2: 
To investigate post-prandial adipose tissue microvascular responses in people with T2D 
(Study 3). 
 
 
Adipose tissue 
dysfunction
Impaired adipose tissue 
microvascular blood flow
Higher inflammation
Resistance training
Obesity
Study 1,2,3 Study 1,2,3
Study 4
T2D Study 1,2,3
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Hypothesis 3: 
Metabolic benefits of RT in people with T2D are linked to improvements in adipose 
tissue microvascular blood flow. 
Aim 3: 
To determine whether RT alters post-prandial adipose tissue microvascular responses 
in people with T2D (Study 4). 
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Chapter 2: General methods 
 
This thesis includes four research projects involving humans. All studies were carried 
out in accordance with the Declaration of Helsinki as revised in 2008. All studies were 
approved by the University of Tasmania Human Ethics Committee (# H14086). 
 
2.1 Recruitment 
 
Participants were recruited through community advertisement such as radio, flyers, 
website and patients from previous studies that gave consent to be contacted for future 
studies. An initial screening was conducted through a health history questionnaire (over 
the phone or via email) to rule of any exclusion criteria prior to their first visit. 
Participants who met the inclusion criteria and exclusion criteria were invited to come 
into the clinic for a screening visit. For T2D people, they were all diagnosed by another 
doctor (general practitioner or endocrinologist) based on their blood glucose levels 
(non-fasting blood glucose >11.0mmol/L, fasting blood glucose >7.0mmol/L, or 2 
hours post oral 75g glucose tolerance test >11.0).  
 
2.2 Participation criteria 
 
Participants who satisfied the inclusion and exclusion criteria were invited to come in 
to clinic centre, Menzies Institute for Medical Research, University of Tasmania for a 
screening visit. 
 
Inclusion criteria:  
1. Aged between 18 - 60 years old.  
2. Healthy or have clinically diagnosed type 2 diabetes.  
3. Normal weight or overweight (BMI ranging from 18- 35 kg/m2).  
4. Have normal or controlled blood pressure (seated brachial blood pressure < 140/90 
mmHg). 
 
Exclusion criteria:  
1. Age <18 years or >60 years.  
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2. Morbidly obese with a BMI ≥ 35 kg/m2.  
3. Cardiac disease with symptoms at rest or inducible with exercise.  
4. History of myocardial infarction or stroke.  
5. Exercise capacity limited by a factor other than claudication, for example:  coronary 
artery disease (angina pectoris), pulmonary disease, arthritis or other musculoskeletal 
complication.  
6. Critical limb ischemia including peripheral artery disease or previous 
revascularisation or other surgical treatment for peripheral artery disease.  
7. History of malignancy within past 5 years (except for non-melanoma skin cancers). 
8. Identification of any medical condition requiring immediate therapeutic intervention.  
9. Uncontrolled hypertension (resting brachial blood pressure ≥140/90 mmHg).  
10. Current smoker.  
11. History of severe liver disease.  
12. History of drug or alcohol abuse.  
13. Elective major surgery during the course of the study.  
14. Pregnancy/lactation.  
15. For T2D participants in the RT program - participation or intention to participate in 
a structured and/or supervised physical activity program during the study period.  
16. Participation or intention to participate in another clinical research study during the 
study period.  
 
2.3 Study protocol 
 
2.3.1 Screening visit 
 
Participants were invited to come into the Menzies Institute for Medical Research 
clinical centre. After signing the informed consent form, their eligibility was confirmed 
by using medical questionnaires, measuring their blood pressure (brachial blood 
pressure was recorded using OMREN HEM 907 device in duplicates one minute apart), 
height and weight. Participants who qualified were invited to complete a physical 
activity questionnaire (IPAQ) to monitor physical activity before each clinic visit. 
Patients who were deemed eligible made an appointment for further testing. 
 
2.3.2 Clinic visit 
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Participants fasted overnight prior to each clinic visit (no food for 12 hours), they 
refrained from vigorous exercise and alcohol for 48 hours prior to testing, and refrained 
from caffeine on the morning of the study. T2D participants stopped taking oral 
medications e.g. metformin, for 48 hours prior to testing. All participants rested in an 
adjustable bed in a semi-recumbent position. Participants resting for 30 mins prior to 
testing and throughout the clinical testing. A small polyethylene catheter was placed 
into an antecubital vein of one arm for blood sampling and for infusing contrast agent 
(Definity). Further details about the clinical testing are outlined below. 
 
2.3.3 Body composition 
 
Body composition was determined for all participants by dual-energy X-ray 
absorptiometry (DEXA, Hologic Delphi densitometer, Hologic, Waltham, USA). 
Briefly, the scanner incorporates a constant potential X-ray source at 76 kV and a K-
edge filter (cerium) to achieve a congruent beam of stable dual-energy radiation, 38 
keV and 70 keV. The beam undergoes attenuation by the tissues as the X-ray beam 
passes through the participant. An experienced radiology technologist performed all 
DEXA examinations and the total body scanning time was about 6 minutes. Total and 
trunk body fat percentage were calculated using Hologic Apex System software version 
4.02 [333]. 
 
2.3.4 Oral glucose challenge and mixed meal challenge  
 
Participants undertook a 2-hour oral glucose challenge (OGC, 50g) or a mixed meal 
challenge (MMC, 1241 kJ; 4.8g fat, 41g carbohydrate, 21.7g protein, and 25.1g sugars) 
to assess their glucose tolerance, microvascular responses and insulin sensitivity. A 
mixed meal was chosen to assess the physiological changes that occur in response to a 
typical meal. A liquid meal was administered to shorten the amount of time needed for 
digestion and absorption. The subjects drank the glucose or the meal within five minutes. 
Before the OGC or the MMC, plasma and serum samples were collected and later sent 
to Royal Hobart Hospital Pathology for the measurement of fasting glucose, lipids, and 
HbA1c. After the ingestion of the drink, blood samples were collected at 15, 30, 60, 90, 
and 120 minutes for the measurement of glucose and insulin concentrations. Plasma 
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glucose was measured by using an YSI analyzer (Yellow Springs Instruments, Yellow 
Springs, OH). Plasma insulin was assayed by using ELISA (Mercodia, Sweden). The 
blood collection tubes were immediately immersed in ice and centrifuged at 2400 g for 
10 min, and samples were frozen and stored at -80°C until analysis. 
 
2.3.5 Adipose tissue microvascular responses by real-time contrast enhanced 
ultrasound (CEU)  
 
Central (truncal) subcutaneous adipose tissue microvascular blood flow was assessed 
by real-time CEU (Figure 2.1). The techniques measures blood vessels that are < 40 µm 
in diameter. However, the majority (>90%) of the vessels in this size range are 
microvascular (5-10 µm diameter). A linear array transducer (L9-3) interfaced with an 
ultrasound system (iU22, Philips Medical Systems, Australia) was placed horizontally 
over the abdomen (immediately right of the umbilicus) and the beam focused on the 
subcutaneous adipose tissue depot. Microbubbles (Definiyt, Lantheus Medical Imaging, 
Melbourne, Australia) were diluted (1.5ml added to 30ml saline) and continuously 
infused intravenously at 2.0-2.6 ml/min (equating to 0.03 ml/min/kg body weight) for 
adipose tissue imaging. Once the systemic microbubble concentration reached steady-
state (5 min), a high energy destructive pulse of ultrasound was transmitted to 
instantaneously destroy microbubbles within the volume of adipose tissue being imaged. 
The reflow dynamics of microbubbles into adipose tissue microvasculature was 
assessed in real-time at baseline and then repeated 1hr following an OGC or a MMC.  
 
Ultrasound settings including gain settings were optimized in humans (after initial in 
vitro experiments) to ensure 1) a high signal-to-noise ratio and 2) to confirm imaging 
within the linear portion of the microbubble concentration versus acoustic intensity 
curve. This is achieved by quantifying tissue and microbubble acoustic intensities under 
a variety of settings and microbubbles infusion rates. Gain settings (90%), mechanical 
index (0.11 for continuous and 1.30 for flash), compression (C=30), depth and focus 
were identical between healthy controls and those with T2D.  
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Figure 2.1: Ultrasound imaging on subcutaneous central adipose tissue (Left) and 
example image containing contrast microbubbles (Right). 
 
2.3.6 Image analysis 
 
Digital image analysis was performed off-line using Qlab (Philips Medical Systems, 
Australia). Images were background subtracted (0.5 sec frames) as published 
previously to eliminate signal from larger blood vessels and tissue per se [334]. 
Analysis of the data was performed identically for baseline and 1h after MMC or OGC. 
Briefly, refilling measures were taken in triplicate and then averaged, with the signal 
from the larger vessels and background subtracted (0.5 second). The microvascular 
refilling curve was created by plotting time (seconds) verses acoustic intensity (AI), 
giving an exponential rise to maximum plot (Figure 2.1). Microvascular volume (A) 
and microvascular filling rate (β) where determined from the graph via SigmaPlot 
graphing software (Systat Software Inc., CA, USA) with the equation: 
 
Y = A(1-e-β(x(t)-bkg(t)))  
Where: 
                X = Time (secs)  
    Y = Acoustic intensity   
                A = Acoustic intensity at the plateau position (an indicator of microvascular 
volume) 
                β = Rate constant which provides a measure of the microvascular filling rate  
  
Skin 
-0 cm 
-3.5 cm 
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                bkg = time of background image  
 
 Microvascular blood flow is calculated by multiplying A and β values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Microvascular blood volume and filling rate determination. Plot was 
constructed after high energy ultrasound pules destroyed microbubbles in imaged 
region at t=0. Microvascular blood volume is indicated by the plateau position (A), and 
the rate of microvascular refilling is indicated but the tangent to the AI rise (β). 
Microvascular blood flow (also known as perfusion) is calculation by A × β. 
  
2.3.7 Inflammatory cytokines 
 
Plasma concentrations of TNF-α, IL-1β, IL-6, CRP, MCP-1 and sVCAM-1 were 
measured using commercially available enzyme-linked immunosorbent assay (ELISA) 
(ELISAKIT, Australia). The protocol was performed as per manufacturer's instructions. 
 
2.3.8 Free fatty acids (FFAs) 
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FFAs levels were determined by using an enzymatic assay kit (Wako Pure Chemical 
Industries, Osaka, Japan). The protocol was performed as per manufacturer's 
instructions. 
 
2.3.9 Resistance training 
 
Some of the T2D participants in the study completed six weeks of a resistance training 
(RT) program. Details of the RT program are described in chapter 6. In summary, 
before and after the RT, participants fasted overnight and came to the clinic to conduct 
the same metabolic and adipose tissue microvascular blood flow testing as described 
above.  
 
2.3.10 Summary of the testing protocol per visit 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Participants fasted overnight prior to their clinic visit. The metabolic and 
adipose tissue microvascular blood flow testing took about 3 hours to complete.  
 
 
2.4 Statistical analysis 
 
Data are presented as the means ± SEM and statistics were performed using SigmaPlot 
(Systat Software, San Jose, CA, USA). One way or Two-way repeated measures 
ANOVA with Student-Newman-Keuls post hoc test was used to compare treatment 
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groups over the time course of experiment where appropriate. Students paired or un-
paired t-test was used to make comparisons between single point measurements where 
appropriate. When data were not normally distributed the Signed Rank Test or 
Wilcoxon rank sum test was performed where appropriate. For categorical variables a 
Fisher’s exact test was performed. Pearson’s bivariate correlations were used to 
evaluate associations. Spearman correlations were used to evaluate associations when 
data were not normally distributed. A value of P < 0.05 was considered as statistically 
significant. 
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Chapter 3: Postprandial adipose tissue microvascular blood flow in healthy 
subjects 
 
3.1 Introduction 
 
Adipose tissue has long been known for its capacity to store triglycerides (TG), dispose 
of glucose after a meal and release FFAs [101, 254]. Blood flow in adipose tissue is 
important for delivery of nutrients (e.g. lipids, glucose), hormones (e.g. insulin) and 
oxygen to the adipocyte, and allows release of hormones and nutrients from the 
adipocyte to the general circulation [232]. To date, most studies on human ATBF, such 
as those of Frayn and colleagues [99, 101, 272] have used 133Xenon washout which 
measures the disappearance of the isotope injected into adipose tissue where faster 
disappearance reflects higher blood flow in adipose tissue. Using this technique, they 
demonstrated that blood flow to adipose tissue increases: (i) post-prandially [235]; (ii) 
in response to an oral glucose challenge [247]; and (iii) during insulin infusion 
(euglycemic hyperinsulinemic clamp) [273]. However, given that capillaries regulate 
nutrient exchange, measuring vascular responses in adipose tissue at the microvascular 
level reveals more information about mechanisms of nutrient exchange. What happens 
at the microvascular level in adipose tissue after the ingestion of a meal has never been 
previously reported. 
 
Nutrient exchange at the microvascular level can occur via an increase in the number 
of microvessels (capillaries) receiving blood flow to augment the endothelial surface 
area, or via an increase in the rate across the microvascular bed which can increase 
nutrient supply. The CEU technique has the capacity to isolate the measurement to the 
microcirculation and dissect different perfusion components – in particular, 
microvascular blood volume (MBV – the number of capillaries being perfused), 
microvascular flow velocity ( – the filling rate of the capillaries being perfused) and 
microvascular blood flow (MBF – which is the product of MBV and ) [280, 281]. 
Whether adipose tissue MBV,  and MBF are increased in response in the post-prandial 
state has not been previously reported.  
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The aim of this chapter was to determine whether adipose tissue microvascular blood 
volume and blood flow increases in the post-prandial state in healthy people, using the 
CEU technique.  
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3.2 Research design and methods 
 
3.2.1 Screening visit  
 
Healthy people were recruited from the community (see Table 3.1). For the screening 
visit, participants were invited to come into the Menzies Institute for Medical Research 
clinical centre to confirm their eligibility by using medical questionnaires. Subjects 
were excluded from the study if they had any of the following characteristics: a history 
of smoking; current pregnancy; cardiac disease; history of severe liver disease; history 
of drug or alcohol abuse; cancer in the last 5 years, elective major surgery during the 
course of the study or taking any medication known to affect glucose metabolism. All 
participants gave written informed consent.  
 
3.2.2 Clinic visit 
 
After the screening visit, 15 healthy controls (6F/9M) were eligible and were invited 
back to the Menzies Institute for Medical Research after an overnight fast. Participants 
refrained from exercise and alcohol 48hr prior to testing. Caffeine was omitted on the 
day of testing. All participants underwent the following testing. 
 
3.2.3 Mixed meal challenge (MMC) 
 
Mixed meal challenge has been described in Chapter 2.3.4. Participants rested for 
approximately 30 min before undergoing a mixed meal challenge (MMC). Subjects 
were then given a liquid MMC (1241 kJ; 4.8g fat, 41.0g carbohydrate, 21.7g protein, 
and 25.1g sugars – Table 3.2). A liquid meal was administered to shorten the amount 
of time needed for digestion and absorption. The subjects drank the meal within 5 min.  
 
The degree of insulin sensitivity was assessed using the Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR)[335] and the Quantitative Insulin 
Sensitivity Check (QUICKI)[336]  using the following equations: 
HOMA-IR = fasting insulin x fasting glucose/405 
QUICKI = 1/(log(fasting insulin)+log(fasting glucose) 
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Fasting insulin is expressed as μU/ml and fasting glucose is expressed as mg/dL. 
Elevated levels of HOMA-IR and low levels of QUICKI indicate a higher degree of 
insulin resistance. 
 
3.2.4 Body composition 
 
All participants underwent a whole body dual energy X-ray absorptiometry (DEXA) 
scan to assess body composition, in particular the amount of total body fat and trunk fat 
as described in Chapter 2.3.3 
 
3.2.5 Real-time contrast enhanced ultrasound (CEU) 
 
Central (truncal) adipose tissue microvascular blood flow was assessed by CEU as 
described in Chapter 2.3.5. Adipose tissue microvascular responses were measured at 
baseline and then repeated 1hr following the MMC. CEU was measured 1 hour 
postprandially as insulin excursions peak at approximately 1 hour following a meal. 
 
3.2.6 Image analysis 
 
Digital image analysis was performed off-line using Qlab (Philips Medical Systems, 
Australia) as described in Chapter 2.3.6. MBV,  and MBF were calculated based on 
curve fitting described in Chapter 2.3.6. 
 
3.2.7 Statistical analysis 
 
Data are presented as the means ± SEM and statistics were performed using SigmaPlot 
(Systat Software, San Jose, CA, USA). One-way repeated measures ANOVA with 
Student-Newman-Keuls post hoc test was used to determine the time course effect of 
the MMC. A Student’s paired t-test was used to determine if there were differences 
between two time points. Pearson’s bivariate correlations were used to evaluate 
associations. Spearman correlations were used to evaluate associations when data were 
not normally distributed. A value of p < 0.05 was considered as statistically significant. 
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3.3 Results 
 
3.3.1 Characteristics of participants 
 
The participant characteristics are presented in Table 3.1. Their anthropometrics, 
clinical chemistries and blood pressure were within a normal range. However, BMI and 
body composition (total fat content) indicate that the participants ranged from normal 
to obese. 
 
3.3.2 Glucose and insulin responses to mixed meal challenge 
 
Figure 3.1 shows the glucose and insulin responses to the MMC. Following the MMC, 
blood glucose rose modestly and reached a peak at 30 min (Figure 3.1A). Blood glucose 
gradually declined over time but remained significantly higher than baseline at 2hrs (p 
< 0.001). Insulin excursion had a similar time course and remained significantly higher 
than baseline during the 2 hrs post ingestion (Figure 3.1B) (p < 0.001). 
 
3.3.3 Adipose tissue microvascular responses to mixed meal challenge (MMC) 
 
Figure 3.2 shows examples of adipose tissue CEU images from a healthy participant 
showing intensity of microbubbles before and 1hr-post MMC (Figures 3.2A and B, 
respectively). Their respective curve fits are shown in Figures 2C and D. The region of 
interest was not identical and not exactly the same size between people. However, the 
same region of interest was used with repeated measures within the same person. 
 
Figure 3.3 shows the average microvascular responses in all participants. MBV was 
significantly elevated 1-hr following the MMC when compare to baseline (p = 0.008) 
(Figure 3.3A).  was not altered by the MMC (Figure 3.3B). MBF was higher compared 
to baseline but was borderline significant (p = 0.088) (Figure 3.3C). 
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3.3.4 Correlates to adipose tissue microvascular responses 
 
Correlations were conducted to determine associations with adipose tissue 
microvascular responses (MBV and MBF) for all healthy subjects (Table 3.3). Figure 
3.4 shows the plots of these significant correlations. Baseline MBV was negatively 
associated with fasting insulin, but positively associated with QUICKI (a surrogate 
marker of insulin sensitivity). MBV following the MMC was positively associated with 
diastolic blood pressure (DBP). Also, baseline MBF was negatively associated with 
total body fat (%) and truncal fat (%), and post meal MBF was negatively associated 
with fasting TG levels.  
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Table 3.1: Characteristics of participants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data expressed as mean ± SEM. None of the subjects was on medication to treat 
obesity or lower lipids.   
Characteristics Mean ± SEM Range 
n 15 - 
Age (years) 46 ± 2 22 - 57 
Sex 6F/9M - 
Height (cm) 170.8 ± 2.8 152.0 -188.0 
Weight (kg) 76.4 ± 2.5 58.4 - 93.0 
BMI (kg/m2) 26.2 ± 0.8 21.7- 33.3 
Body Fat   
    Total fat (%) 28.1 ± 2.1 16.6 - 47.0 
    Trunk fat (%) 27.8 ± 2.1 16.7 - 46.7 
Fasting glucose (mmol/L) 4.63 ± 0.18 2.67 -5.46 
Fasting insulin (pmol/L) 42.6 ± 3.5 24.1- 80.1 
HbA1c   
    % 5.33 ± 0.06 4.80 -5.90 
    mmol/mol 34.7 ± 0.7 29.0 -41.0 
Insulin Sensitivity Indices   
    HOMA-IR 1.27 ± 0.12 0.61 -2.51 
    QUICKI 0.37 ± 0.01 0.33 - 0.42 
Blood Pressure   
    SBP (mmHg) 123 ± 2 107 - 139 
    DBP (mmHg) 78 ± 2 65 - 89 
Lipids   
    Cholesterol (mmol/L) 4.95 ± 0.23 3.30 - 6.80 
    Triglyceride (mmol/L) 0.86 ± 0.07 0.38 - 1.51 
    HDL (mmol/L) 1.49 ± 0.09 0.90 - 2.30 
    LDL (mmol/L) 3.06 ± 0.21 1.50 - 4.50 
    FFA (mmol/L) 0.40 ± 0.05 0.09 - 0.71 
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Table 3.2: Macronutrient composition of the mixed meal challenge (MMC). 
 
 
 
 
 
 
  
  MMC 
Energy (kJ) 1241 
Protein (g) 21.7 
Fat (g) 4.8 
Carbohydrate (g) 41.0 
           Sugars (g) 25.1 
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Table 3.3: Correlates of adipose tissue MBV and MBF response to MMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pearson’s correlation was used between normally distributed variables. Spearman 
correlation was used if any of the variables were not normally distributed. Bold indicate 
significant correlations. MBV: Microvascular blood volume; MBF: microvascular 
blood flow; MMC: mixed meal challenge. 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Baseline MBV MMC MBV Baseline MBF MMC MBF 
r p r p r p r p 
Body fat                 
Total fat (% ) -0.348 0.204 0.124 0.660 -0.713 0.002 -0.154 0.585 
Trunk fat (%) -0.369 0.176 0.049 0.863 -0.654 0.008 -0.191 0.496 
Metabolism         
Fasting glucose 
(mmol/L) -0.211 0.441 -0.264 0.332 0.154 0.575 -0.446 0.092 
Glucose AUC 
(mmol/L.120min) -0.007 0.980 -0.118 0.676 0.154 0.575 -0.385 0.156 
Fasting insulin (pmol/L) -0.540 0.038 -0.365 0.181 -0.507 0.052 -0.197 0.482 
Insulin AUC 
(mmol/L.120min) 0.018 0.944 -0.100 0.714 0.136 0.620 0.093 0.734 
HbA1c (%) 0.078 0.783 -0.061 0.828 0.178 0.514 -0.199 0.477 
QUICKI 0.622 0.013 0.400 0.140 0.429 0.107 0.154 0.584 
Fasting serum 
triglyceride (mmol/L) -0.311 0.259 -0.374 0.170 -0.302 0.263 -0.626 0.013 
Fasting plasma FFA 
(mmol/L) 0.282 0.309 0.057 0.839 0.129 0.639 -0.304 0.270 
Blood pressure         
SBP (mmHg) 0.146 0.604 0.288 0.299 0.189 0.489 0.227 0.415 
DBP (mmHg) 0.385 0.156 0.703 0.003 0.271 0.319 0.261 0.069 
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Figure 3.1: Flowchart of the number of participants screened, excluded, studied, and 
analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrollment
Assessment for 
eligibility (n=15)
Mixed meal 
challenge (n=15)Allocation
Analysis
Completed study 
and included in 
analysis (n=15)
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Figure 3.2: Blood glucose (A) and plasma insulin (B) timelines in response to the 
mixed meal challenge. Data are means ± SEM. Repeated-measures one-way ANOVA 
was used to determine if there were differences over the time course of the experiment. 
† P < 0.01 vs. baseline.  
  
 
A B 
 
† † † 
† 
† 
† 
† 
† 
† 
† 
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Figure 3.3: Examples of adipose tissue CEU images showing intensity of microbubbles 
before (A) and after (B) a 1hr mixed meal challenge (MMC) in a healthy individual. 
Red line indicates the region of interest for analysis. Corresponding curve fits after a 
destructive pulse of ultrasound before (C) and after (D) a 1hr MMC. 
  
 
C D 
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Figure 3.4: Adipose tissue microvascular responses the MMC in healthy people. MBV 
(A), β (B) and MBF (C) at time 0min (baseline) and 60min after MMC. Data are means 
± SEM. A Student’s paired t-test was used to determine if there were differences 
between the two time points. 
†
P < 0.01 vs. baseline MMC; §P = 0.088 vs. baseline MMC. 
MBV: Microvascular blood volume; MBF: microvascular blood flow; MMC: mixed 
meal challenge. 
 
 
 
 
 
 
B 
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§ 
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Figure 3.5: Statistically significant correlations for baseline MBV and fasting insulin 
(A), baseline MBV and QUICKI (B), MMC MBV and DBP (C), baseline MBF and 
total body fat (D),baseline MBF and trunk fat (E) and MMC MBF and fasting TG (F). 
 
C 
A 
 
R = -0.540 
P = 0.038 
 
B 
 
R = 0.622 
P = 0.013 
 
R = 0.703 
P = 0.003 
 
 
D 
R = -0.713 
P = 0.002 
 
 
E 
R = -0.654 
P = 0.008 
 
 
F 
R = -0.626 
P = 0.013 
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MBV: Microvascular blood volume; MBF: microvascular blood flow; MMC: mixed 
meal challenge. 
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3.4 Discussion 
 
This is the first study to explore postprandial adipose tissue microvascular responses in 
healthy people. The key findings of this study were that adipose tissue MBV and MBF 
responses were significantly elevated following the MMC. This microvascular action 
may improve delivery of hormones (e.g. insulin) and nutrients (e.g. glucose and lipids) 
from the MMC to adipose tissue for storage. 
 
Insulin increases MBF and recruits capillaries in skeletal muscle [277, 337-341]. 
Importantly, the MMC also markedly increases muscle MBV [342], thereby expanding 
the endothelial surface for nutrient exchange, and this vascular process is an important 
physiological response to facilitate nutrient/hormone delivery to skeletal muscle [340, 
343]. Gersh and colleagues have suggested that adipose tissue possesses the ability to 
recruit capillaries to the same extend as that found in skeletal muscle [344], however 
these studies have not been previously conducted. The current study confirms that the 
MMC increases MBF and recruits capillaries (MBV) in adipose tissue in healthy 
subjects (Figure 3.2 and 3.3). Therefore increases in MBV and/or MBF may facilitate 
uptake of nutrients from the meal into adipose tissue.  
 
The participants in the current study were all non-diabetic individuals (based on their 
fasting clinical chemistries). However, there was a large range in their BMI and their 
amount of body fat, spanning from healthy-to-overweight-to-obese. During obesity, 
adipose tissue expands via hypertrophy (increased adipocyte size) or via hyperplasia 
(increased adipocyte number), with the former being metabolically detrimental [106]. 
The current study demonstrated that the degree of obesity is a strong correlate of 
adipose tissue MBF (Figure 3.4). This is not a surprising finding given that others have 
demonstrated a similar relationship between bulk ATBF and obesity [235, 272, 345] 
and it is well established that with adipocyte hypertrophy, as occurs in obesity, there is 
a reduction in capillary density [346]. However, this is the first study to demonstrate 
this negative association between ATBF and adiposity at the microvascular level in 
humans. 
 
It is intriguing that the relationship with MBF and adiposity was stronger than MBV 
considering the reduction in capillary density might be expected to reduce MBV. It was 
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anticipated that the degree of obesity would be a stronger predictor of MBV and it was 
surprising to find that their baseline MBV did not correlate with body fat. Histology 
was not conducted to assess capillary density and as such can only speculate that the 
capillary density was similar between lean and obese individuals, or that those with 
obesity had a greater number of capillaries perfused at rest. However, this study has 
demonstrated that those individuals with a greater amount of total body fat or trunk fat 
had a lower baseline adipose tissue MBF.   
 
Using 133Xe, ATBF increases (i) post-prandially [235]; (ii) in response to an oral 
glucose challenge [247]; and (iii) during insulin infusion (euglycemic hyperinsulinemic 
clamp) [273] and these vascular responses are impaired in subjects with IR [100, 234, 
275] . It is not surprising that in the current project there is a positive relationship 
between the degree of IR (based on fasting insulin levels and QUICKI) and MBV. 
However, this is the first study in humans to demonstrate this relationship at the 
microvascular level in humans. Given that a positive association was observed between 
diastolic blood pressure and post-prandial MBV, one possibility is that higher blood 
pressure increases the number of capillaries open during the MMC. However the 
potential mechanism behind the positive association between MBV and blood pressure 
needs to be further investigated. 
 
In summary, the current chapter has demonstrated that 1) adipose tissue microvascular 
responses are augmented in the post-prandial state in healthy people and 2) this 
microvascular effect is lower in people with obesity and with early signs of IR. 
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Chapter 4: Comparison between oral glucose challenge and mixed meal 
challenge on adipose tissue microvascular blood flow in healthy subjects 
 
4.1 Introduction 
 
Chapter 3 demonstrated that the MMC stimulates adipose tissue MBV and MBF in 
healthy people. This effect was blunted in healthy people who had a higher amount of 
body fat (in particular trunk fat). This microvascular action may regulate delivery of 
nutrients from the MMC (e.g. lipids and glucose) to adipose tissue for storage. The 
effects seen in adipose tissue in Chapter 3 were similar to the responses seen in skeletal 
muscle [338]. MBF and MBV in skeletal muscle are elicited by a meal or insulin 
infusion and that this response is impaired during IR such as obesity [342, 347]. 
  
It is plausible that the mechanism of this impairment is the same in the two tissues (i.e. 
skeletal muscle and adipose tissue) because they share a common insulin signalling 
pathway linking meal ingestion and vasodilation of the microvasculature [348]. It has 
been established that the mechanism in skeletal muscle is via insulin causing NO release 
from endothelium via endothelial insulin receptor, stimulation of Akt, and activation of 
eNOS [349, 350]. Mechanisms of vasodilation in adipose are less well-defined, but NO 
blockade similarly impairs the ATBF response to oral glucose loading [247], and others 
have shown that ATBF increases in response to insulin infusion [273, 276]. However, 
the increase in ATBF in response to insulin infusion is lower than that of oral glucose 
loading, suggesting additional vasodilatory signals may be involved [273]. Notably, β 
adrenergic receptor antagonism partially blocks the ATBF response to oral glucose 
loading, suggesting possible sympathetic nervous involvement in the vasodilation [247]. 
 
An additional intriguing observation that has recently been reported is that in skeletal 
muscle MBV increases in response to a MMC but is markedly impaired in response to 
an oral glucose challenge despite a similar level of hyperinsulinemia [351]. However, 
a direct comparison of adipose tissue microvascular responses to an MMC and an oral 
glucose challenge has not been made to date. 
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Therefore, the aim of this chapter is to compare the adipose tissue microvascular 
responses to an OGC and a MMC, while matching plasma insulin levels based on 
previous work [342]. 
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4.2 Research design and methods 
 
4.2.1 Screening visit  
 
Healthy people were recruited from the community (see Table 4.1). For the screening 
visit, participants were invited to come to the Menzies Institute for Medical Research 
clinical centre to confirm their eligibility by using medical questionnaires. Subjects 
were excluded from the study if they had any of the following characteristics: a history 
of smoking; current pregnancy; cardiac disease; history of severe liver disease; cancer 
within the last 5 years, history of drug or alcohol abuse; elective major surgery during 
the course of the study; or taking any medication known to affect glucose metabolism. 
Based on their fasting blood glucose (< 7.0mmol/L) and HbA1c (< 6.5%), participants 
were non-diabetic individuals. All participants gave written informed consent.  
 
4.2.2 Clinic visit 
 
After the screening visit, eligible participants were invited back to the Menzies Institute 
for Medical Research after an overnight fast. Participants refrained from exercise and 
alcohol for 48hr prior to testing and caffeine was omitted on the day of testing. 
Participants either underwent a MMC or an OGC and the following testing performed. 
 
4.2.3 Oral glucose challenge (OGC) and mixed meal challenge (MMC) 
 
OGC and MMC has been described in chapter 2.3.4. 24 participants competed OGC 
and 15 of them volunteered to participant in MMC. 
 
4.2.4 Body composition 
 
All participants underwent a whole body dual energy X-ray absorptiometry (DEXA) 
scan to assess body composition, in particular the amount of total body fat and trunk 
fat as described in Chapter 2.3.3.  
 
4.2.5 Real-time contrast enhanced ultrasound (CEU)  
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Central (truncal) adipose tissue microvascular blood flow was assessed by CEU as 
described in Chapter 2.3.5. Adipose tissue microvascular responses were measured at 
baseline and then repeated 1hr following the OGC or MMC.  
 
4.2.6 Image analysis 
 
Digital image analysis was performed off-line using Qlab (Philips Medical Systems, 
Australia) as described in Chapter 2.3.6. MBV,  and MBF were calculated based on 
curve fitting described in Chapter 2.3.6. 
  
4.2.7 Statistical analysis 
 
Data are presented as the means ± SEM and statistics were performed using SigmaPlot 
(Systat Software, San Jose, CA, USA). Categorical variables are reported as numbers 
and percentages. Student’s t-test was used to compare end point measurements between 
groups. When data were not normally distributed the Wilcoxon rank sum test was 
performed. For categorical variables a Fisher’s exact test was performed. Two-way 
repeated measures ANOVA with Student-Newman-Keuls post hoc test was used to 
compare treatment groups over the time course of experiment. Pearson’s bivariate 
correlations were used to evaluate associations. Spearman correlations were used to 
evaluate associations when data were not normally distributed. A value of P < 0.05 was 
considered as statistically significant. 
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4.3 Results 
 
4.3.1 Characteristics of participants 
 
The participant characteristics are presented in Table 4.2. There were no statistically 
significant differences in age, sex, anthropometrics, blood pressure or clinical 
chemistries between groups. 
 
4.3.2 Glucose and insulin responses to oral glucose challenge (OGC) and mixed 
meal challenge (MMC) 
 
Figure 4.1 shows the glucose and insulin responses to the OGC and MMC. Following 
the OGC and MMC, plasma glucose increased significantly and the glucose excursion 
was higher following the OGC when compare with MMC (Figure 4.1A). Consequently, 
the glucose area under the time course curve (AUC) during the OGC was markedly 
higher (p < 0.001) compared with the MMC (Figure 4.1B). However, the plasma insulin 
time course and the insulin AUC during the OGC and MMC were similar (Figure 4.1C 
and D). 
 
4.3.3 Microvascular blood volume (MBV) and microvascular blood flow (MBF) 
responses to oral glucose challenge (OGC) and mixed meal challenge (MMC) 
 
Figure 4.2 shows adipose tissue MBV and MBF responses at baseline and one hour 
following the OGC or MMC. Both the OGC and MMC increased MBV to a similar 
level above baseline (p = 0.031 and p = 0.008 versus baseline respectively) (Figure 
4.2A). β was not significantly different at baseline or in response to the OGC and the 
MMC (Figure 4.2B). Both the OGC and MMC stimulated MBF to a similar extent but 
was only borderline significant (p = 0.061 and p = 0.088 versus baseline respectively) 
(Figure 4.2C).  
 
4.3.4 Correlates to Microvascular blood volume (MBV) and microvascular blood 
flow (MBF) response to oral glucose challenge (OGC) 
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Correlations were conducted to determine associations with adipose tissue 
microvascular responses (MBV and MBF) to the OGC (Table 4.3) and the MMC (Table 
4.4). Only baseline MBF was negatively associated with total body fat (%), truncal fat 
(%) and triglyceride (TG). Compared with correlates of adipose tissue MBV and MBF 
response to MMC (Table 4.4), baseline MBF was negatively associated with total body 
fat and trunk fat in MMC and OGC.  
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Table 4.1: Macronutrient composition of the oral glucose challenge (OGC) and 
mixed meal challenge (MMC). 
 
 
 
 
 
 
 
  
  MMC OGC 
Energy (kJ) 1241 837 
Protein (g) 21.7 - 
Fat (g) 4.8 - 
Carbohydrate (g) 41.0 50 
        Sugars (g) 25.1 50 
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Table 4.2: Characteristics of participants. Data are expressed as mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OGC: oral glucose challenge; MMC: mixed meal challenge.  
Characteristics OGC MMC P value 
n 24 15 − 
Age (years) 47 ± 2 46 ± 2 0.678 
Sex 9F/15M 6F/9M − 
Height (cm) 172.6  ± 2.4 170.8 ± 2.8 0.309 
Weight (kg) 76.8 ± 2.2 76.4 ± 2.5 0.699 
BMI (kg/m2) 25.8  ± 0.6 26.2 ± 0.8 0.366 
Body Fat    
    Total fat (%) 27.0 ± 1.8 28.1 ± 2.2 0.701 
    Trunk fat (%) 26.6 ± 1.6 27.8 ±2.1 0.670 
Fasting glucose 
(mmol/L) 4.97  ± 0.14 4.63 ± 0.18 0.423 
Fasting insulin (pmol/L) 45.0 ± 2.6 42.6 ± 3.5 0.777 
HbA1c    
    % 5.35  ± 0.05 5.33 ± 0.06 0.835 
    mmol/mol 35.00  ± 0.55 34.73 ± 0.73 0.776 
Insulin Sensitivity Indices   
    HOMA-IR 1.45  ± 0.11 1.27 ± 0.12 0.943 
    QUICKI 0.37  ± 0.01 0.37 ± 0.01 0.521 
Blood Pressure    
    SBP (mmHg) 123  ± 2 123 ± 2 0.708 
    DBP (mmHg) 76  ± 2 78 ± 2 0.944 
Lipids    
    Cholesterol (mmol/L) 5.10  ± 0.21 4.95 ± 0.23 0.922 
    Triglyceride (mmol/L) 0.88  ± 0.09 0.86 ± 0.07 0.477 
    HDL (mmol/L) 1.42  ± 0.06 1.49 ± 0.09 0.737 
    LDL (mmol/L) 3.19  ± 0.19 3.06 ± 0.21 0.893 
    FFA (mmol/L) 0.43 ± 0.03 0.40 ± 0.05 0.628 
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Table 4.3: Correlates of adipose tissue MBV and MBF response to the OGC 
Characteristics 
Baseline MBV OGC MBV Baseline MBF OGC MBF 
r p r p r p r p 
Body fat                 
Total fat (% ) -0.065 0.764 -0.054 0.807 -0.454 0.029 -0.145 0.504 
Trunk fat (%) -0.029 0.894 -0.050 0.822 -0.504 0.014 -0.140 0.518 
Metabolism 
        
Fasting glucose (mmol/L) 0.273 0.205 -0.047 0.831 0.200 0.357 0.258 0.231 
Glucose AUC 
(mmol/L.120min) 
-0.055 0.799 -0.088 0.689 0.132 0.542 0.146 0.501 
Fasting insulin (pmol/L) 0.054 0.802 -0.071 0.743 -0.403 0.056 -0.055 0.799 
Insulin AUC 
(mmol/L.120min) 
0.274 0.192 -0.019 0.930 -0.391 0.058 -0.244 0.246 
HbA1c (%) 0.117 0.588 0.232 0.288 0.129 0.551 -0.020 0.926 
QUICKI -0.067 0.761 0.132 0.549 0.258 0.231 -0.022 0.919 
Fasting serum triglyceride 
(mmol/L) 
-0.011 0.959 -0.132 0.542 -0.508 0.014 -0.180 0.407 
Fasting plasma FFA 
(mmol/L) 
0.003 0.987 0.029 0.896 -0.341 0.110 -0.347 0.103 
Blood pressure 
        
SBP (mmHg) 0.311 0.149 -0.120 0.584 0.163 0.452 0.095 0.663 
DBP (mmHg) 0.133 0.539 -0.118 0.592 -0.106 0.623 0.046 0.830 
 
Pearson’s correlation was used between normally distributed variables. Spearman 
correlation was used if any of the variables were not normally distributed. Bold indicate 
significant correlations. MBV: Microvascular blood volume; MBF: microvascular 
blood flow; OGC: oral glucose challenge. 
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Table 4.4: Correlates of adipose tissue MBV and MBF response to the MMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pearson’s correlation was used between normally distributed variables. Spearman 
correlation was used if any of the variables were not normally distributed. Bold indicate 
significant correlations. MBV: Microvascular blood volume; MBF: microvascular 
blood flow; MMC: mixed meal challenge. (Data from Chapter 3 Table 3.3)  
 
 
 
 
 
 
 
 
 
 
 
Characteristics Baseline MBV MMC MBV Baseline MBF MMC MBF 
r p r p r p r p 
Body fat                 
Total fat (% ) -0.348 0.204 0.124 0.660 -0.713 0.002 -0.154 0.585 
Trunk fat (%) -0.369 0.176 0.049 0.863 -0.654 0.008 -0.191 0.496 
Metabolism         
Fasting glucose 
(mmol/L) -0.211 0.441 -0.264 0.332 0.154 0.575 -0.446 0.092 
Glucose AUC 
(mmol/L.120min) -0.007 0.980 -0.118 0.676 0.154 0.575 -0.385 0.156 
Fasting insulin (pmol/L) -0.540 0.038 -0.365 0.181 -0.507 0.052 -0.197 0.482 
Insulin AUC 
(mmol/L.120min) 0.018 0.944 -0.100 0.714 0.136 0.620 0.093 0.734 
HbA1c (%) 0.078 0.783 -0.061 0.828 0.178 0.514 -0.199 0.477 
QUICKI 0.622 0.013 0.400 0.140 0.429 0.107 0.154 0.584 
Fasting serum 
triglyceride (mmol/L) -0.311 0.259 -0.374 0.170 -0.302 0.263 -0.626 0.013 
Fasting plasma FFA 
(mmol/L) 0.282 0.309 0.057 0.839 0.129 0.639 -0.304 0.270 
Blood pressure         
SBP (mmHg) 0.146 0.604 0.288 0.299 0.189 0.489 0.227 0.415 
DBP (mmHg) 0.385 0.156 0.703 0.003 0.271 0.319 0.261 0.069 
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Figure 4.1: Flowchart of the number of participants screened, excluded, studied, and 
analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrollment
Assessment for 
eligibility (n=23)
Oral glucose 
challenge and mixed 
meal challenge 
(n=23)
Allocation
Analysis
Completed study and included 
in analysis 
Oral glucose challenge (n=23)
Mixed meal challenge (n=15)
8 did not complete 
mixed meal challenge
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Figure 4.2: Plasma glucose and insulin levels in response to an OGC and a MMC. 
Plasma glucose (A) and insulin (C) time course in response to an OGC and MMC, and 
2-hr glucose (B) and insulin (D) area under the curve during an OGC and MMC. Data 
are means ± SEM for each group. Repeated-measures two-way ANOVA was used to 
determine if there were differences between treatment groups over the time course of 
the experiment, or Student’s t-test (or Wilcox Rank Sum Test if data not normally 
distributed) was used for single point measurements. When a significant difference was 
found, pairwise comparisons by the Student–Newman–Keuls test was used to 
determine treatment differences. *P < 0.05 vs. MMC; †P < 0.01 vs. MMC. MBV: 
Microvascular blood volume; MBF: microvascular blood flow; OGC: oral glucose 
challenge; MMC: mixed meal challenge. 
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Figure 4.3: Adipose tissue microvascular responses to an OGC and MMC in healthy 
people. MBV (A), β (B) and MBF (C) at time 0 min (baseline) and 1-hr after OGC and 
MMC. Data are means ± SEM for each group.  Repeated-measures two-way ANOVA 
was used to determine if there were differences between treatment groups over the time 
course of the experiment. When a significant difference was found, pairwise 
comparisons by the Student–Newman–Keuls test was used to determine treatment 
differences. *P < 0.05 vs. baseline OGC; ##P < 0.01 vs. baseline MMC; §P = 0.061 vs. 
baseline OGC; +P = 0.088 vs. baseline MMC. MBV: Microvascular blood volume; 
MBF: microvascular blood flow; OGC: oral glucose challenge; MMC: mixed meal 
challenge. 
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4.4 Discussion 
 
The present study for the first time compared the adipose tissue microvascular 
responses to an OGC and a MMC. Despite different macronutrient profiles, and blood 
glucose excursions, the OGC and MMC produced a similar increase in MBV and MBF 
in adipose tissue of healthy people. Both OGC and MMC produced similar insulin 
responses at 1hr following ingestion suggesting that insulin may play an important role 
in controlling perfusion (and nutrient delivery) to the adipocyte after a meal.   
 
Adipose tissue MBV has been previously reported to increases in response to a 75g 
load of glucose in healthy people [275]. While most studies in humans focus on the 
MBV [274-276], the contribution of other important components of the 
microcirculation in adipose tissue, such as β and MBF, have been ignored. The current 
study confirms that MBV increases in response to an oral glucose load in healthy people, 
but also demonstrates that microvascular velocity (β) is not affected. Importantly, this 
study has established for the first time in humans that adipose tissue microvascular 
responses (whether MBV, β or MBF) are similar between the MMC and OGC despite 
very different macronutrient profiles and glycaemic loads.  
 
The OGC produced a much higher blood glucose excursion when compared to the 
MMC. This is interesting because the vascular endothelium is susceptible to damage 
during prolonged hyperglycaemia and a growing body of literature suggests that acute 
hyperglycaemia can also impair vascular function in healthy people [352-354]. 
Ingestion of glucose (50g glucose) impairs brachial artery flow mediated dilation to a 
similar extent as a high glycemic-index meal (50g carbohydrate) when compared to a 
low glycemic-index meal (50g carbohydrate) [352]. Notably, it has been reported that 
the microvascular response to insulin is switched from dilation to constriction by the 
presence of hyperglycaemia [340]. Acute hyperglycaemia has been observed to 
diminish endothelial vascular responsiveness in healthy humans via activation of PKC 
[353] or reduced NO bioavailability [354]. Animal and cell culture studies have also 
demonstrated a direct effect of high glucose exposure to augment production of 
vasoconstrictors such as endothelin-1 [355] and prostanoids [356]. Given that pre-
capillary arterioles are responsible for the regulation of capillary networks in all tissues, 
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it is perhaps surprising that OGC did not impair the microvascular responses under 
similar levels of hyperinsulinemia.  
 
Triglycerides are reported to be negatively associated with total ATBF [100, 234]. The 
current study shows that baseline MBF in adipose tissue is negatively associated with 
triglyceride levels. This is interesting as it highlights the possibility that interventions 
to stimulate ATBF may have remarkable influence on reducing hypertriglyceridemia. 
This relationship was only observed in the post-prandial state in the group allocated to 
the MMC. This is an interesting observation given that the correlation was based on 
baseline levels of MBF and TG. Although TG levels were not statistically different 
between groups, the MMC group had a narrower range of fasting TG levels, which may 
explain the lack of association between TG and MBF in this group during fasting 
conditions. However, MBF was negatively associated with TG levels (whether fasting 
or post-prandial) in both OGC and MMC groups. Different ranges in plasma insulin, 
HOMA-IR and BP may also explain the different levels of significance with the 
associations with MBF and MBF in the MMC versus OGC groups. However a common 
feature between the OGC and MMC group is negative relationship with obesity. 
 
In Chapter 3, the degree of obesity was found to be a strong modifier of adipose tissue 
microvascular blood flow (Figure 3.4). In this chapter, baseline MBF was also 
negatively associated with total body fat and truncal fat regardless of whether the group 
were allocated to MMC or OGC. This is not a surprising finding given that others have 
demonstrated a similar relationship between bulk ATBF and obesity [235, 272, 345]. It 
is well established that with adipocyte hypertrophy, as occurs in obesity, there is a 
reduction in capillary density [346], so, the greater degree of obesity similarly affects 
the ability to increase adipose tissue microvascular blood flow. 
 
Our previous study has shown that OGC, which raised plasma insulin levels to a similar 
extent as the MMC, impaired microvascular responses (both MBV and MBF) in 
skeletal muscle of healthy individuals [351]. However, the present study provided that 
the OGC and MMC produced a similar increase in MBV and MBF in adipose tissue of 
healthy people. This may suggest that the mechanism of stimulating microvascular 
blood flow in skeletal muscle and adipose tissue is different.  
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In summary, the current chapter has demonstrated that 1) insulin (rather than the 
composition of the meal) is a key regulator of adipose tissue microvascular blood flow, 
2) acute hyperglycaemia does not impair adipose tissue microvascular blood flow and 
3) the degree of obesity affects the ability to increase adipose tissue microvascular 
blood flow. A limitation of the study is that a cross-over randomised study design was 
not used to compare the adipose tissue microvascular responses to an OGC and a MMC. 
It is now important to do follow up studies by matching total macronutrient profile (with 
the exception that one MMC contains glucose only as the source of carbohydrate 
whereas the other MMC contains complex carbohydrates) to see if similar observations 
are made with two different diets with different glycaemic indexes. 
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Chapter 5: Impairments in adipose tissue microcirculation in type 2 diabetes 
assessed by real-time contrast-enhanced ultrasound 
 
5.1 Introduction 
 
Adipose tissue is a highly dynamic endocrine organ, capable of secreting a number of 
hormones and pro-inflammatory mediators that regulate appetite, energy metabolism, 
and insulin action [357]. The dysregulation of normal adipose tissue function, as is the 
case with obesity, leads to exaggerated release of FFAs and pro-inflammatory cytokines 
into the circulation resulting in ectopic lipid deposition, low-grade chronic 
inflammation, and IR [117].   
 
There has been renewed interest over the past decade in the effect of blood flow on 
metabolism and inflammation in adipose tissue in obesity, IR and T2D [122, 233-235, 
237]. Blood flow in adipose tissue is important for delivery of macronutrients (e.g. 
glucose and triglycerides/lipoproteins), hormones (e.g. insulin) and oxygen to the 
adipocyte. Conversely, blood flow through adipose tissue also enables release of 
hormones (e.g. adiponectin) and metabolites (e.g. FFAs) from the adipocyte into the 
general circulation [232]. Impaired blood flow in adipose tissue has been proposed to 
cause hypoxia, resulting in tissue remodelling and the recruitment and activation of 
macrophages, leading in turn to amplified release of pro-inflammatory cytokines [107, 
108]. In addition, impaired ATBF may also reduce nutrient exchange (e.g. glucose and 
triglycerides/lipoproteins) and hormone (e.g. insulin) delivery after a meal , leading to 
whole body IR [100]. 
  
 
Chapter 3 and 4 demonstrated that adipose tissue MBV and MBF were elevated in the 
post-prandial state of healthy subjects and this effect was blunted with a greater degree 
of obesity and IR (assessed by surrogate markers of IR). Whether adipose tissue MBV, 
β and MBF are impaired in people with T2D has not been investigated. Finally, whether 
impairments in microcirculation in adipose tissue are linked to the metabolic syndrome 
(the degree of adiposity, inflammation, blood pressure, IR, glucotoxicity and 
dyslipidemia) remains to be determined. The aim of the current study was to 
characterise adipose tissue microvascular responses in healthy people and those with 
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T2D using CEU, and establish whether there is an adipose tissue metabolic-linked 
microvascular phenotype in obesity and T2D.  
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5.2 Research design and methods 
 
5.2.1 Screening visit  
 
Healthy controls and people with T2D were recruited from the community (see Table 
5.1 for their baseline characteristics). Participants with T2D had a previous clinical 
diagnosis by a doctor. During screening, participants were invited to the Menzies 
Institute for Medical Research Clinical Centre to establish eligibility by using medical 
questionnaires. Exclusion criteria from the study were: a history of smoking, current 
pregnancy, cardiac disease, history of severe liver disease, history of drug or alcohol 
abuse, cancer in the past 5 years, or major elective surgery during the course of the 
study. All participants provided written informed consent.  
 
5.2.2 Clinic visit 
 
After the screening visit, 24 healthy controls (9F/15M) and 21 subjects with T2D 
(8F/13M) were invited back after an overnight fast for testing. Participants refrained 
from exercise and alcohol for 48hrs prior to testing. Caffeine was omitted on the day of 
testing. Subjects with T2D refrained from taking their oral diabetes medication for 
48hrs prior to testing. This is because these medications could affect results especially 
blood glucose levels. All participants were subjected to the following tests. 
 
5.2.3 Body composition  
 
Following height and weight assessment, body composition was determined by dual-
energy X-ray absorptiometry (DEXA) as described in Chapter 2.3.3.  
 
5.2.4 Oral glucose challenge (OGC)  
 
Oral glucose challenge has been described in chapter 2.3.4.  
 
5.2.5 Real-time contrast enhanced ultrasound (CEU)  
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Central (truncal) adipose tissue microvascular blood flow was assessed by CEU as 
described in Chapter 2.3.5. Background adipose tissue signal in the absence of contrast 
was identical between groups (healthy controls = 2.1±0.1 AI; T2D = 2.0±0.1 AI; 
p=0.417).  
 
The arterial concentration of microbubbles was assessed by imaging the brachial artery 
at an infusion rate of 0.5ml/min to avoid signal saturation. When the acoustic intensity 
was scaled up to the dose infused for adipose tissue imaging, healthy controls and T2D 
had similar arterial levels (96.6±6.3 AI versus 87.4±7.4 AI, p=0.348). 
 
5.2.6 Image analysis  
 
Digital image analysis was performed off-line using Qlab (Philips Medical Systems, 
Australia) as described in Chapter 2.3.6 
 
5.2.7 Inflammatory cytokines  
 
Measurement of inflammation cytokines has been described in chapter 2.3.7.  
 
5.2.8 Statistical analysis 
 
Data are presented as the means ± SEM and statistics were performed using SigmaPlot 
(Systat Software, San Jose, CA, USA). Student’s t-test was used to compare end point 
measurements between controls and T2D. When data were not normally distributed the 
Wilcoxon rank sum test was performed. For categorical variables a Fisher’s exact test 
was performed. Two-way repeated measures ANOVA with Student-Newman-Keuls 
post hoc test was used to compare treatment groups over the time course of experiment. 
Pearson’s bivariate correlations were used to evaluate associations. Spearman 
correlations were used to evaluate associations when data were not normally distributed. 
A value of p < 0.05 was considered as statistically significant. 
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5.3 Results 
 
5.3.1 Baseline characteristics of subjects 
 
The baseline characteristics of participants are presented in Table 5.1. Subjects with 
T2D had significantly higher body weight, BMI, total body fat (%), trunk fat (%), 
fasting blood glucose, fasting plasma insulin, HbA1c, HOMA-IR, systolic blood 
pressure (SBP), diastolic blood pressure (DBP), serum triglyceride and plasma FFA, 
and lower HDL and QUICKI (quantitative insulin sensitivity check index) when 
compare to control participants. Interestingly, LDL was significantly lower in people 
with T2D compared with healthy controls and is most likely reflective of greater statin 
use in this group. Medications and co-morbidities are also shown in Table 5.1.  
 
5.3.2 Glucose and insulin responses to oral glucose challenge (OGC) 
 
Blood glucose levels in people with T2D were significantly higher than controls at 
every time point (Figure 5.1A). Accordingly, the glucose area under curve (AUC) over 
the 2hrs in the T2D cohort was significantly higher (p < 0.001) compared with controls 
(Figure 5.1B). While fasting insulin levels were higher in the people with T2D, there 
were no differences in the time-course of plasma insulin levels during the OGC. As 
such, the insulin AUC for control subjects and those with T2D were also similar (Figure 
5.1D). 
 
The T2D cohort had elevated fasting insulin levels (Figure 5.1 and Table 5.1) but 
similar insulin response to the OGC when compared to healthy controls. This indicates 
that the T2D participants have some form of pancreatic dysfunction, as is the case with 
most people with T2D [358], but not considered late phase T2D. The T2D patients also 
did not have the additional complications of T2D that are more common in late phase 
T2D (e.g. self-reported nephropathy, retinopathy, neuropathy, or a history of heart 
attack or stroke). 
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5.3.3 Microvascular blood volume (MBV) and microvascular blood flow (MBF) 
responses to oral glucose challenge (OGC)  
 
Figure 5.2 shows examples of adipose tissue contrast enhanced CEU images showing 
intensity of microbubbles before and 1hr-post OGC in healthy controls (Figures 5.2A 
and B, respectively) and those with T2D (Figures 5.2D and E, respectively). 
Corresponding curve fits after a destructive pulse of ultrasound in controls (Figure 5.2C) 
and those with T2D (Figure 5.2F) are also presented. 
 
Figure 5.3 represents the averaged adipose tissue MBV, β and MBF values at baseline 
and 1 hour into a 50g OGC in control subjects and those with T2D. There was no 
statistically significant difference in MBV between control and T2D subjects at baseline 
(Figure 5.3). However, adipose tissue MBV in controls was significantly elevated 1 hr 
after the OGC (p = 0.020) and this response was completely absent in the people with 
T2D, being significantly lower than controls at the same time point (p = 0.009) (Figure 
5.3A). β was not significantly different between healthy and T2D at baseline or in 
response to the OGC (Figure 5.3B). In healthy controls, MBF was not significantly 
elevated post OGC. However, baseline MBF in T2D appeared lower than the control 
group (p = 0.079) and was significantly lower than controls 1hr into the OGC (p = 0.011; 
Figure 5.3C).  
 
5.3.4 Pro-inflammatory cytokines 
 
Pro-inflammatory cytokines measured by ELISA at baseline are shown in Figure 5.4. 
There were no statistically significant differences observed in TNF-α, IL-6, CRP, MCP-
1, IL-1β or sVCAM-1 between control subjects and those with T2D (Figure 5.4). 
 
5.3.5 Correlates of adipose tissue microvascular blood volume (MBV) and 
microvascular blood flow (MBF) 
 
Correlations were conducted to determine associations with adipose tissue 
microvascular responses (MBV and MBF) for all subjects (Table 5.2). The data of the 
diabetes and control group combined for the correlations to provide a greater range of 
data distribution. These variables were classified into four groups: body fat composition, 
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metabolism, blood pressure, and inflammation. Baseline MBF, but not baseline MBV, 
was negatively associated with truncal fat (%). However, both MBV and MBF in 
response to the OGC were negatively associated with truncal fat (%). 
 
All markers of metabolism were significantly associated with baseline MBF and OGC 
MBF, with the exception of FFAs which were only associated with OGC MBF. In 
summary, fasting blood glucose, glucose AUC during the OGC, HbA1c, fasting insulin, 
TG and FFA levels were negatively associated with baseline and/or OGC MBF. 
QUICKI (a surrogate marker of insulin sensitivity) correlated positively with MBF. 
QUICKI was the only metabolic variable that correlated with MBV, being positively 
associated with the MBV response to the OGC. Fasting TG and FFA levels correlated 
negatively with MBF but not MBV. Systolic blood pressure correlated positively with 
baseline MBV. Inflammation was not associated with adipose tissue MBV or MBF at 
rest or in response to the OGC. 
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Table 5.1: Characteristics of participants 
Characteristic  Control Type 2 diabetes P value 
n 24 21 - 
Age (years) 47 ± 2 52  ± 2 0.157 
Sex 9F/15M 8F/13M 1.000 
Diabetes Duration (yr) - 9 ± 5 - 
Hypertension, n (%) 1 (4) 10 (48) 0.001 
Hypercholesterolemia, n (%) - 13 (62) <0.001 
Height (cm) 172.6 ± 2.4 171.5 ± 1.7 0.460 
Weight (kg) 76.8 ± 2.2 94.6 ± 5.4 0.001 
BMI (kg/m2) 25.8 ± 0.6 31.7 ± 1.5 <0.001 
Body Fat    
    Total fat (% ) 27.0  ± 1.8 32.2 ± 1.4  0.030 
    Trunk fat (%) 26.6 ± 1.6 34.2 ± 1.3 0.001 
Fasting glucose (mmol/L) 4.97 ± 0.14 9.82 ± 0.71  <0.001 
Fasting insulin (pmol/L) 45.0 ± 2.6 113.2 ± 14.4 <0.001 
HbA1c    
    % 5.35 ± 0.05 7.65 ± 0.34 <0.001 
    mmol/mol 35.0 ± 0.6 58.0 ± 4.4 <0.001 
Insulin Sensitivity Indices    
    HOMA-IR 1.45 ± 0.11 7.19 ± 1.12 <0.001 
    QUICKI 0.37 ± 0.01 0.30 ± 0.01 <0.001 
Blood Pressure    
    SBP (mmHg) 123  ± 2 133  ± 3 0.006 
    DBP (mmHg) 76  ± 2 85  ± 2 0.003 
Lipids    
    Cholesterol (mmol/L) 5.10 ± 0.21 4.65 ± 0.22 0.251 
    Triglyceride (mmol/L) 0.88 ± 0.09 1.89 ± 0.20 <0.001 
    HDL (mmol/L) 1.42 ± 0.06 1.23 ± 0.10 0.013 
    LDL (mmol/L) 3.19 ± 0.19 2.58 ± 0.17 0.026 
    FFA (mmol/L) 0.43 ± 0.03 0.58 ± 0.04 0.009 
Medication, n (%)    
Metformin - 20 (95) <0.001 
Sulphonurea - 2 (10) 0.212 
GLP-1 RA - 2 (10) 0.212 
DPP4 inhibitor - 3 (14) 0.094 
SGLT2 inhibitor - 1 (5) 0.467 
Insulin - 2 (10) 0.212 
ACEi/ARB - 7 (33) 0.003 
Diuretic - 4 (19) 0.040 
Ca2+ channel blocker 1 (4) 5 (24) 0.083 
Statin - 10 (48) <0.001 
 Other  12 (50) 12 (57) 0.767 
 
Data are mean ± SEM. Student’s t-test (or Wilcoxon Rank Sum Test if data not 
normally distributed) was used to determine differences between groups when the data 
were continuous. The Fisher Exact test was used to compare categorical data. ACEi 
(angiotensin converting enzyme inhibitor), ARB (angiotensin receptor blocker), DPP4 
(dipeptidyl peptidase 4), GLP-1 RA (glucagon-like peptide-1 receptor agonist), SGLT2 
(sodium-glucose cotransporter 2). 
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Table 5.2: Correlates of adipose tissue MBV and MBF (control and T2D participants 
combined). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pearson’s correlation was used between normally distributed variables. Spearman 
correlation was used if any of the variables were not normally distributed. Bold indicate 
significant correlations. MBV: Microvascular blood volume; MBF: microvascular 
blood flow; OGC: oral glucose challenge. 
 
 
 
 
 
 
Characteristics 
Baseline MBV OGC MBV Baseline MBF OGC MBF 
r p r p r p r p 
Body fat         
Total fat (% ) 0.129 0.403 -0.221 0.149 -0.279 0.067 -0.286 0.060 
Trunk fat (%) 0.193 0.209 -0.298 0.049 -0.429 0.004 -0.381 0.011 
Metabolism         
Fasting glucose 
(mmol/L) 0.016 0.920 -0.286 0.06 -0.362 0.016 -0.367 0.015 
Glucose AUC 
(mmol/L.120min) -0.092 0.551 -0.240 0.116 -0.424 0.004 -0.376 0.012 
Fasting insulin 
(pmol/L) 0.047 0.759 -0.278 0.068 -0.453 0.002 -0.374 0.012 
HbA1c (%) -0.041 0.792 -0.18 0.241 -0.327 0.031 -0.398 0.008 
QUICKI -0.037 0.809 0.328 0.03 0.498 0.001 0.48 0.001 
Fasting serum 
triglyceride 
(mmol/L) 0.008 0.956 -0.279 0.067 -0.499 0.001 -0.302 0.046 
Fasting plasma 
FFA (mmol/L) 0.098 0.525 -0.116 0.452 -0.226 0.139 -0.322 0.033 
Blood pressure         
SBP (mmHg) 0.335 0.026 -0.080 0.608 0.058 0.707 -0.021 0.890 
DBP (mmHg) 0.139 0.365 -0.159 0.303 -0.205 0.182 -0.065 0.672 
Heart rate (bpm) 0.061 0.686 -0.280 0.062 -0.316 0.035 -0.299 0.046 
Inflammation         
TNF-α (pg/mL) 0.106 0.493 0.003 0.985 -0.087 0.575 -0.120 0.436 
IL-1β (pg/mL) 0.025 0.871 -0.059 0.703 0.124 0.419 -0.109 0.478 
IL-6  (pg/mL) 0.136 0.378 -0.26 0.089 -0.02 0.896 0.065 0.672 
CRP (ng/mL) 0.111 0.471 -0.08 0.604 -0.065 0.675 -0.098 0.525 
MCP-1 (pg/mL) 0.118 0.443 -0.129 0.403 -0.209 0.171 -0.206 0.063 
sVCAM-1 (ng/mL) 0.006 0.969 0.219 0.153 -0.030 0.843 0.098 0.525 
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Figure 5.1: Flowchart of the number of participants screened, excluded, studied, and 
analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrollment
Assessment for 
eligibility 
Controls (n=24)
T2D (n=21)
Oral glucose 
challenge 
Controls (n=24)
T2D (n=21)
Allocation
Analysis
Completed study and 
included in analysis 
Controls (n=24)
T2D (n=21)
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Blood glucose and insulin levels during the oral glucose challenge (OGC) 
(50g) in control (n=24) and type 2 diabetes (T2D, n=21) people. Blood glucose (A) and 
insulin (C) timelines in response to an OGC, and the calculated 2-hr glucose (B) and 
insulin (D) area under the curve (AUC) during the OGC. Data are means ± SEM for 
each group. Repeated-measures two-way ANOVA was used to determine if there were 
differences between treatment groups over the time course of the experiment, or 
Student’s t-test (or Wilcoxon Rank Sum Test if data not normally distributed) was used 
for single point measurements. When a significant difference was found, pairwise 
comparisons by the Student–Newman–Keuls test was used to determine treatment 
differences.  †P < 0.01 vs. control. 
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(A) (B) (C) 
(D) (E) (F) 
Skin 
Adipose tissue 
          +  
microbubbles 
- 0cm - 
- 3.5cm - 
Skin 
Adipose tissue 
          + 
 microbubbles 
- 0cm - 
- 3.5cm - 
OGC 
(MBV=1.6AI 
 β=0.20 1/sec 
MBF=0.32 AI/sec) 
Baseline 
(MBV=0.8 AI 
β=0.111/sec 
MBF=0.09 AI/sec) 
OGC 
(MBV=0.3AI  
β=0.07 1/sec 
MBF=0.02 AI/sec) 
Baseline 
(MBV=0.3AI 
β=0.09 1/sec 
 MBF=0.03 AI/sec) 
Figure 5.3: Examples of adipose tissue contrast enhanced images showing intensity of microbubbles before and after a 1hr 
OGC in controls (A and B, respectively) and those with type 2 diabetes (T2D, D and E, respectively). The box in each figure 
represents the region of interest used for data analysis. Corresponding curve fits after a destructive pulse of ultrasound in 
controls (C) and those with T2D (F). MBV: Microvascular blood volume; MBF: microvascular blood flow; OGC: oral glucose 
challenge. 
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Figure 5.4: MBV, β and MBF responses to OGC in control (n=24) and type 2 diabetes 
(T2D, n=21) people. MBV (A), β (B) and MBF (C) at baseline and 1hr post-OGC. Data 
are means ± SEM for each group. Repeated-measures two-way ANOVA was used to 
determine if there were differences between treatment groups over the time course of 
the experiment. When a significant difference was found, pairwise comparisons by the 
Student–Newman–Keuls test was used to determine treatment differences.  *P < 0.05 
vs. control baseline; †P < 0.05 vs. control OGC; ‡P < 0.01 vs. control OGC; §P = 0.079 
vs. control baseline. MBV: Microvascular blood volume; MBF: microvascular blood 
flow; OGC: oral glucose challenge. 
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Figure 5.5: Fasting plasma TNF-α (A), IL-1β (B), IL-6 (C), CRP (D), MCP-1 (E) and 
sVCAM-1 (F) concentrations in control (n=24) and type 2 diabetes (T2D, n=21) people. 
Data are means ± SEM. Differences between treatment groups were assessed by 
Student’s t-test (Wilcoxon Rank Sum Test if data not normally distributed).  
 
(A) (B) 
(C) (D) 
(E) (F) 
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5.4 Discussion 
 
The present study demonstrates that adipose tissue MBF at rest and in response to 
ingestion of glucose is markedly impaired in individuals with T2D. Impaired adipose 
MBF responses were associated with higher amounts of body fat, increased TG and 
FFA concentrations, and glucose intolerance and hyperglycaemia. Surprisingly, no 
differences in circulating inflammatory markers between healthy and T2D individuals 
were observed. Therefore, it is concluded that impaired microvascular responses in 
adipose tissue of people with T2D are not conditionally linked to systemic inflammation, 
rather, are associated with IR, hyperglycaemia and dyslipidaemia. 
 
There is only one study to date that has specially investigated microvascular responses 
in adipose tissue in humans with T2D. In that study adipose tissue MBV in response to 
a 75g oral glucose load was impaired in T2D, however MBF was not assessed [275]. 
The current study confirms that MBV increases in response to an oral glucose load in 
healthy people and that this response is not apparent in people with T2D. Importantly, 
this study has established for the first time in humans that adipose tissue MBF, rather 
than MBV, is more markedly impaired (by ~70%) in T2D both basally and in response 
to an OGC. This is important because a growing body of literature suggest that adipose 
tissue is hypoxic during obesity (which is common in T2D)[108] and these data suggest, 
that MBF is more closely linked to adipose tissue metabolic disturbances than MBV.  
 
The current study focused on subcutaneous adipose tissue. Whether central (visceral) 
adipose tissue also displays the same microvascular abnormalities is yet to be confirmed. 
A limitation of the study was that the T2D participants were on a variety of medications 
when compared to the healthy controls (Table 5.1). Although diabetes-related 
medications were omitted for 48hrs prior to attending the clinic for testing, participants 
were still taking other medications (e.g. statins and anti-hypertensives) which may have 
contributed, at least in part, to variations in blood flow responses between groups. 
 
In the current study, people with T2D had a significantly higher amount of total body 
and trunk fat compared with healthy controls (Table 5.1). Data from the current study 
indicate that the degree of adiposity, in particular truncal fat (%), is negatively 
associated with MBF and MBV measures, and the association was strongest with 
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baseline MBF (Table 5.2). These findings are not surprising given that a negative 
correlation was observed between body fat and MBF in the healthy group alone in 
Chapter 4 (Table 4.3). Thus, it appears that the degree of obesity rather than T2D per 
se is significantly associated with impaired adipose tissue microvascular responses. 
This is not a surprising finding given that others have demonstrated a similar 
relationship between bulk ATBF and obesity [235, 272, 345] and it is well established 
that with adipocyte hypertrophy, as occurs in obesity, there is a reduction in capillary 
density [346]. Belick et al established that obese and insulin resistant (db/db) mice have 
markedly larger adipocytes and impaired MBV and MBF [122]. However, the current 
study is the first to demonstrate a negative association between adiposity and both MBV 
and MBF in humans. It is intriguing that the relationship with MBF was stronger than 
MBV considering the reduction in capillary density might be expected to reduce MBV. 
It was anticipated that MBV would be lower in people with T2D and were surprised to 
find that their baseline MBV were similar to controls. This was also similarly observed 
by Tobin et al [275]. Histology to assess capillary density was not conducted in the 
current study and as such it has been speculated that 1) the capillary density was similar 
between controls and T2D or 2) there were fewer capillaries but a greater proportion 
were open at baseline in T2D. Given that a positive association between systolic blood 
pressure and baseline MBV was observed, one possibility is that the higher systolic 
blood pressure observed in T2D helps capillary patency at rest leaving less capillaries 
available for recruitment during the OGC. In chapter 3, the MBV in response to the 
MMC positively correlated with diastolic blood pressure (DBP) but not with systolic 
blood pressure (SBP). However, in chapter 5, this correlation disappeared when 
controls and T2D were combined together. Instead, we found a positive association 
between SBP and baseline MBV. It is important to note that the correction in the control 
cohort was stronger (r=0.703) than the combination of controls and T2D (r=0.335). The 
reasons for this are unknown but are important to follow-up in a larger trial. However, 
the greater reduction in MBF may have significant implications for the ability of 
adipose tissue to rapidly clear post-prandial nutrients such as triglycerides/lipoproteins 
in the obese state.  
 
It is thought that as the adipocyte undergoes hypertrophy, insufficient microvascular 
blood supply to the adipocyte leads to hypoxia, macrophage recruitment and conversion 
of macrophages from an inactive state (M2) to an active state (M1) in which they are 
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reported to release TNF-α, IL-6, IL-1β and MCP-1 [85, 127]. Previous work has also 
demonstrated that activated macrophages are present in high numbers in subcutaneous 
adipose tissue of obese individuals and that weight loss decreases the number of 
activated macrophages [359]. It was proposed that the marked reduction in adipose 
tissue MBF in the T2D participants would be associated with a pro-inflammatory 
phenotype. However, no association between adipose tissue microvascular responses 
and inflammation was found. Further, no evidence of a systemic pro-inflammatory state 
in the T2D cohort was observed. This was confirmed by measuring systemic levels of 
well-known pro-inflammatory mediators (TNF-α, IL-6, MCP-1, CRP and IL-1β) and 
an additional marker of vascular inflammation (sVCAM). Tam and colleagues have 
reported that diet induced (28 day dietary intervention) weight gain and IR occurs in 
the absence of a significant inflammatory state in humans [360]. Other work suggests 
that inflammation is not conditionally linked with obesity-mediated IR [361, 362] and 
the current findings support this lack of association. However, adipose tissue levels of 
pro-inflammatory markers, histology on adipose tissue to assess the degree of 
macrophage recruitment and activation, or the assessment of adipose tissue oxygenation 
were not conducted in the current project. Inflammation may have been seen in this 
study if an older cohort or those with a higher amount of adiposity had been recruited. 
Nevertheless, in the study found no evidence of an adipose tissue microvascular-linked 
pro-inflammatory state in people with T2D.  
 
Given that a microvascular-linked pro-inflammatory state was not observed in the T2D 
cohort, the next step was to determine whether impairments in microvascular responses 
in adipose tissue were related to glucotoxicity and/or dyslipidaemia, which are known 
to be associated with T2D. At baseline and in response to the OGC, MBF was 
significantly correlated with all insulin sensitivity/glucoregulatory function measures 
(fasting glucose, OGC AUC, fasting insulin, HbA1c, and QUICKI). In contrast, only 
QUICKI was associated with MBV. In chapter 4, the results have shown that insulin is 
a key regulator of adipose tissue microvascular blood flow. In this chapter, MBF 
response in people with T2D was markedly impaired, but the insulin response was very 
similar. Therefore, blood vessels in adipose tissue of people with T2D are insulin 
resistant. Belcik et al demonstrated that both MBV and MBF correlated negatively with 
fasting blood glucose and glucose AUC after an intraperitoneal insulin challenge in 
obese, insulin resistant mice [122]. Increases in skeletal muscle MBV in response to 
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insulin is important for muscle glucose disposal because it helps deliver glucose to the 
myocyte [277, 338, 342]. The current study demonstrates that MBF, rather than MBV 
in adipose tissue may be more important for glucoregulatory function and insulin 
sensitivity. Rates of glucose uptake in adipose tissue following a meal are smaller than 
those of skeletal muscle, so it is uncertain whether the improvement in adipose tissue 
MBF in healthy people following the glucose load promotes glucose uptake or whether 
excess circulating glucose in the people with T2D impairs microvascular function in 
adipose tissue. Rates of glucose uptake in the adipose tissue bed (arterio-venous glucose 
difference x flow or with isotopic glucose tracers) were not measured in the current 
study which will be required in future experiments to help address this question.   
 
FFA and TG are reported to be negatively associated with total ATBF [100, 234]. The 
current study reports for the first time that MBF in adipose tissue has a similar negative 
association with FFA and TG levels. High blood viscosity due to elevated TG levels 
(ranging from ~0.2 to ~10mM by Intralipid infusion) has been demonstrated to affect 
coronary microvascular responses to hyperaemia [363]. Although people with T2D in 
the current study had elevated TG levels, this increase (1.89 ± 0.20 mM) is on the low 
end of the TG-blood viscosity range reported by Rim et al and as such is unlikely to 
affect blood viscosity in T2D subjectsin the present study. However, direct assessment 
of blood viscosity would be necessary to exclude this possibility. The direction of the 
association between TG and MBF is currently not known, however these data have 
implications for impaired microvascular responses in adipose tissue in the involvement 
of dyslipidaemia and ectopic fat accumulation.  
 
In summary, the findings demonstrate an impairment in both MBV and MBF in adipose 
tissue of people with T2D. Chapter 4 demonstrated that the degree of obesity 
(independent of T2D) is a strong modifier of adipose tissue microvascular blood flow. 
However, there was only one association between microvascular responses and other 
metabolic parameters (blood glucose, insulin sensitivity, lipid profile) in the healthy 
group alone (Chapter 4) suggesting that T2D with concomitant obesity has additional 
detrimental impact on adipose tissue microvascular-linked lipidaemia and glycaemia, 
but not systemic inflammation. However, the direction of these associations are 
unknown and further experiments will help characterize the cause-and-effect. 
Improving microvascular function in adipose tissue may be a novel approach to prevent 
91 
 
pathogenesis of obesity related complications such as IR, dyslipidemia and 
glucotoxicity. A limitation of this study is that we did not match BMI between groups 
(control versus T2D). 
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Chapter 6: Metabolic benefits of resistance training in type 2 diabetes are not 
linked to improvements in adipose tissue microvascular blood flow 
 
6.1 Introduction 
 
Resistance training (RT) is recommended for people with T2D to improve overall 
cardiometabolic health [315, 316]. Specifically, RT improves insulin sensitivity, 
glycaemia, circulating lipids, body composition (i.e. increases muscle mass and reduces 
body fat) and is protective against cardiovascular disease (e.g. lowers blood pressure, 
aortic stiffness, and improves endothelial function) [364].  
 
Keske and colleagues have recently demonstrated that in addition to these 
cardiometabolic benefits, six weeks of RT markedly enhances skeletal muscle 
microvascular blood flow (MBF) in T2D subjects in responses to an oral glucose 
challenge (OGC) [299]. Importantly, this enhanced skeletal muscle microvascular 
response was tightly linked to improvements in overall glycaemic control including 
reductions in fasting blood glucose and HbA1c levels, and improvements in glucose 
tolerance following an OGC [299]. Skeletal muscle is an important site for glucose 
disposal following a meal [365], and a greater MBF response following RT improves 
delivery of glucose and hormones (such as insulin) to the myocyte to improve glucose 
disposal [280]. These skeletal muscle microvascular-linked improvements with RT 
occurred independent of changes in body composition positioning the microvasculature 
in skeletal as an important regulator of overall glucose homeostasis.  
 
Adipose tissue is also an important site for glucose disposal following a meal (albeit 
smaller than skeletal muscle) [366]. Perhaps more importantly, adipose tissue is a key 
site for the release of FFAs and a storage site for triglycerides [123]. Similar to skeletal 
muscle, adipose tissue has a dynamic microvascular blood supply to help promote the 
delivery and release of macronutrients such as oxygen, glucose and lipids [116]. 
Chapter 5 reported impairments in MBF and the recruitment of capillaries (MBV) in 
response to an OGC in central subcutaneous adipose tissue of people with T2D. These 
microvascular impairments in adipose tissue, in particular MBF, were associated with 
a greater degree of obesity, IR, hypertriglyceridemia, elevated plasma FFA levels, 
hyperglycaemia and glucose intolerance. Therefore improving microvascular function 
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in adipose tissue may be a novel approach to prevent pathogenesis of obesity related 
complications such as IR, dyslipidaemia and glucotoxicity.  
 
While previous studies have shown exercise training improves microvascular flow (and 
consequently metabolic function) in skeletal muscle, there have been no studies 
assessing the impact of exercise training on adipose tissue microvascular responses in 
people with T2D. The aim of this study is to determine if six weeks of RT augments 
adipose tissue microvascular responses in sedentary people with T2D and whether this 
is paralleled by improvements in IR, hyperglycaemia and dyslipidaemia. 
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6.2 Research design and methods 
 
The study was carried out in accordance with the Declaration of Helsinki as revised in 
2008. The study protocol was approved by Tasmania Health & Medical Human 
Research Ethics Committee.  
 
6.2.1 Screening visit  
 
Sedentary (self-reported <30 min of moderate exercise per week) people with T2D were 
recruited through community advertisement. During screening, participants were 
invited to the Menzies Institute for Medical Research Clinical Centre to establish 
eligibility by using a medical questionnaire. Participants were included in the study if 
they were between 18 and 60 years of age, had a clinical diagnosis of T2D, and were 
normal weight to overweight (BMI 19 -35 kg/m2). Participants were excluded from the 
study if they participated in any kind of resistance exercise or performed more than 
low-intensity walking. Additional exclusion criterion included having a BMI >35 kg/m2 
or a personal history of smoking, cardiovascular disease, stroke, myocardial infarction, 
uncontrolled hypertension (seated brachial blood pressure >160/100 mmHg), 
peripheral arterial disease, pulmonary disease, arthritis/muscular skeletal disease, 
malignancy within the past five years, or severe liver disease. A medical practitioner 
examined each participant to confirm eligibility to participate in an exercise program. 
 
 
6.2.2 Clinic visit 
 
After the screening visit, participants were invited back after an overnight fast. 
Participants refrained from exercise and alcohol 48 hr prior to testing and caffeine on 
the morning of the study. Diabetes medications were stopped for 48 hr prior to testing. 
Participants were asked to complete a physical activity questionnaire (IPAQ) to confirm 
eligibility that they were sedentary. All participants were subjected to the following 
tests. 
 
6.2.3 Body composition 
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Subjects underwent a whole body scan to assess body composition before and after RT 
by dual-energy X-ray absorptiometry (DEXA) from soft tissue composition as 
described in Chapter 2.3.3.  
 
6.2.4 Oral glucose challenge (OGC) 
 
Oral glucose challenge (OGC) has been described in chapter 2.3.4. OGC was assessed 
before and after RT. 
 
6.2.5 Real-time contrast enhanced ultrasound (CEU) 
 
Central (truncal) subcutaneous adipose tissue microvascular blood flow was assessed 
by real-time CEU as described in Chapter 2.3.5. The reflow dynamics of microbubbles 
into adipose tissue microvasculature was assessed in real-time at baseline and then 
repeated 1hr following an OGC before and after RT. 
 
6.2.6 Image analysis  
 
Digital image analysis was performed off-line using Qlab (Philips Medical Systems, 
Australia) as described in Chapter 2.3.6 
 
6.2.7 Resistance Training (RT) Intervention 
 
The six-week RT programme used in this study was based on previous RT studies [293, 
299]. RT was performed three days per week at the same time at a local fitness centre 
in Hobart, Tasmania, Australia (All Aerobic Fitness). The training regime was divided 
into a full body workout on Monday and Friday, with core and stability exercises on 
Wednesday. The full body workout used a mixture of free-weights and resistance 
machines. One set of each resistance exercise was performed to complete muscle failure 
(6-15 reps) and included in the order: leg press, lateral pull-down, chest press, weighted 
lunges, seated row, back fly, bicep curl, incline chest press, dumbbell shoulder press, 
leg extension, leg curl, dips, lateral shoulder raise, triceps extension, dumbbell deadlift, 
and push-ups. As for core and stability exercises, the workouts used a range of 
resistance-focused techniques such as dumbbell sit-ups, medicine ball toss, leg-lifts, 
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plank positions, burpees, and weighted farmer’s walk, but they were not limited to these. 
These workouts were continually modified to match increased strength and fitness.  
 
Each session was limited to one hour. All resistance exercises were recorded with the 
load incrementally increased [maintained between 65%-85% of calculated 1 repetition 
maximum (1RM)] as strength was increased to ensure progression. Participants were 
encouraged to drink water if they need before, during and after RT. Also, participants 
underwent a DEXA scan the week before returning to the clinic for repeated a series of 
cardiometabolic testing as described above.  
 
6.2.7 Inflammatory cytokines/markers  
 
Measurement of inflammation cytokines has been described in chapter 2.3.7.  
 
6.2.8 Statistical analysis 
 
Data are presented as the means ± SEM. Student’s paired t-test was used to compare 
end point measurements between Pre-RT and Post-RT. When data were not normally 
distributed or Wilcoxon Signed Rank Test was performed. For all continuous variables, 
a two-way repeated measures ANOVA (interactions: time: 0 and 60 min group: pre-RT 
and post-RT) followed by a Student–Newman–Keuls post-hoc was performed.  
Significance was set at p<0.05. Tests were performed using SigmaStat™ statistical 
program (Systat Software, San Jose, CA, USA). 
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6.3 Results 
 
6.3.1 Characteristics of subjects before and after RT 
 
The characteristics of participant before and after RT are presented in Table 6.1. As 
expected, following six weeks of RT, participants had significant reductions in total 
body fat (p = 0.002) and trunk fat (p = 0.023). These changes in body composition 
occurred without changes in overall body weight or BMI. Fasting blood glucose (p = 
0.006), HbA1c (p = 0.007), HOMA-IR (p = 0.005) and fasting serum triglyceride levels 
(p = 0.029) were significantly lower following RT, whereas fasting plasma insulin, 
QUICKI, blood pressure, total cholesterol, HDL, LDL and FFA were unaffected. 
 
6.3.2 Blood glucose and insulin responses to the oral glucose challenge (OGC) 
before and after RT 
 
Figure 6.1 shows the time course of blood glucose and plasma insulin levels before and 
after a 50 g OGC. Following RT, plasma glucose levels were significantly lower during 
the OGC except at 90 min (Figure 6.1A) and the area under the glucose time curve 
(Figure 6.1B) was significantly lower (p = 0.014). Plasma insulin levels during the OGC 
were significantly lower at 15, 30 and 60 min post-OGC (Figure 6.1C) and area under 
the insulin time curve was also significantly lower after RT (p = 0.036, Figure 6.1D).  
 
6.3.3 Adipose tissue microvascular blood volume (MBV) and microvascular blood 
flow (MBF) responses to oral glucose challenge (OGC) before and after RT 
 
Adipose tissue MBV and MBF responses to the OGC before and after RT are shown in 
Figure 6.2. Baseline MBV (p = 0.102),  (p = 0.885), and MBF (p = 0.225) did not 
improve following RT. Similarly, there were no significant changes in MBV,  or MBF 
responses to the OGC after six weeks of RT (Figure 6.2). 
 
6.3.4 Effect of RT on circulating pro-inflammatory markers 
 
Pro-inflammatory cytokines measured by ELISA before and after RT are shown in 
Figure 6.3. There was a significant increase in TNF-α and sVCAM-1 post-RT. However, 
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there were no statistically significant differences observed in IL-6, CRP, MCP-1, or IL-
1β before and after RT.  
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Table 6.1: Characteristics of study participants before and after RT. Data expressed 
as Mean ± SEM (n=18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Student’s t-test (or Signed Rank Test if data not normally distributed) was used to 
determine differences. ACEi (angiotensin converting enzyme inhibitor), ARB 
(angiotensin receptor blocker), DPP4 (dipeptidyl peptidase 4), GLP-1 RA (glucagon-
like peptide-1 receptor agonist), SGLT2 (sodium-glucose cotransporter 2). 
 
 
Characteristics  Pre-RT Post-RT P value 
Age (years) 52 ± 2 - - 
Sex 7F/11M - - 
Diabetes Duration (years) 9 ± 1 - - 
Diabetes Medication 
   
    Lifestyle only (%) 1 (6) - - 
    Metformin (%) 17 (94) - - 
    Sulphonylurea (%) 2 (11) - - 
    Insulin (%) 2 (11) - - 
    GLP-1 RA (%) 2 (11) - - 
    DPP4 inhibitor (%) 1 (6) - - 
    SGLT2 inhibitor (%) 1 (6) - - 
Height (cm) 170.9 ± 1.88 - - 
Weight (kg) 94.69 ± 6.13 90.47 ± 3.88 0.421 
BMI (kg/m2) 31.94 ± 1.75 30.75 ± 1.02 0.596 
Body Fat 
   
    Total fat (% ) 32.06 ± 1.57 31.14 ± 1.61 0.002 
    Trunk fat (%) 34.10 ± 1.45 33.09 ± 1.45 0.023 
Fasting glucose (mmol/L) 10.23 ± 0.78 9.04 ± 0.69 0.006 
Fasting insulin (pmol/L) 111.87 ± 15.43 98.42 ± 13.11 0.108 
HbA1c 
   
    % 7.78 ± 0.37 7.44 ± 0.34 0.007 
Insulin Sensitivity Indices 
   
    HOMA-IR 7.76 ± 1.24 5.72 ± 0.96 0.005 
    QUICKI 0.30 ± 0.01 0.31 ± 0.01 0.078 
Blood Pressure 
   
    SBP (mmHg) 132.8 ± 3.4 130.4 ± 2.7 0.388 
    DBP (mmHg) 84.1 ± 2.5 83.3 ± 2.2 0.602 
Lipids 
   
    Cholesterol (mmol/L)    4.69 ± 0.24 4.50 ± 0.23 0.260 
    Triglyceride (mmol/L) 1.82 ± 0.23 1.47 ± 0.016 0.029 
    HDL (mmol/L) 1.27 ± 0.11 1.28 ± 0.10 0.808 
    LDL (mmol/L) 2.60 ± 0.19 2.55 ± 0.20 0.734 
    FFA (mmol/L) 0.59 ± 0.05 0.56 ± 0.06 0.485 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Flowchart of the number of participants screened, excluded, studied, and 
analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrollment
Assessment for 
eligibility (n=21)
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for six weeks (n=21)Allocation
Analysis
Completed study and 
included in analysis 
(n=18)
1 withdrew
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Figure 6.2:  Blood glucose (A) and plasma insulin (C) timelines in response to an OGC, 
and 2-hr glucose (B) and insulin (D) area under the curve during a 50g OGC. Data are 
means ± SEM for each group. Repeated-measures two-way ANOVA was used to 
determine if there were differences between treatment groups over the time course of 
the experiment, or Student’s paired t-test (or Signed Rank Test if data not normally 
distributed) was used for single point measurements. When a significant difference was 
found, pairwise comparisons by the Student–Newman–Keuls test was used to 
determine treatment differences. *P < 0.05 vs. control; †P < 0.01 vs. control. 
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Figure 6.3: Adipose tissue MBV, β and MBF responses to OGC before and after RT 
in people with T2D. MBV (A), β (B) and MBF (C) at baseline (time 0-min) and after 
OGC (time 60-min). Data are means ± SEM for each group. Repeated-measures two-
way ANOVA was used to determine if there were differences between treatment groups 
over the time course of the experiment. When a significant difference was found, 
pairwise comparisons by the Student–Newman–Keuls test was used to determine 
treatment differences. Dotted and solid lines represent baseline and post OGC responses 
in healthy people (data taken from Chapter 4). MBV: Microvascular blood volume; 
MBF: microvascular blood flow; OGC: oral glucose challenge. 
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Figure 6.4: Fasting plasma TNF-α (A), IL-1β (B), IL-6 (C), CRP (D), MCP-1 (E) and 
sVCAM-1 (F) concentrations in type 2 diabetes (T2D, n=21) people.  Data are means 
± SEM. Student’s paired t-test (or Wilcoxon Signed Rank Test if data not normally 
distributed) was used for single point measurements. 
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6.4 Discussion 
 
This is the first study to assess the impact of exercise training on microvascular 
responses in adipose tissue of people with T2D. The study demonstrated that the well-
known metabolic and anthropometric benefits of six weeks of RT are not paralleled by 
improvements in adipose tissue MBV, microvascular flow velocity () or MBF. These 
results are surprising given that poor adipose tissue microvascular responses, in 
particular MBF, are associated with a greater degree of adiposity, dyslipidaemia, and 
glucotoxicity. Therefore, it is concluded that six weeks of RT in people with T2D 
produced favourable effects of glycaemic regulation, circulating lipids and body 
composition, however these effects occurred without a concomitant increase in adipose 
tissue microvascular responses at rest or during an OGC. In chapter 4, our findings have 
shown that insulin is a key regulator of adipose tissue microvascular blood flow. In this 
chapter, MBV and MBF response before and after RT were not different, but the insulin 
responses were improved. There are a number of insulin sensitive tissues in the body 
(liver, adipose tissue and skeletal muscle. Therefore, the improvement in insulin levels 
of RT may be indicative of liver and skeletal muscle being more insulin sensitive rather 
than adipose tissue. 
  
There are very few studies that have investigated the effects of chronic exercise 
interventions on human ATBF. To date, most studies on human ATBF, such as those 
of Frayn and colleagues [99, 101, 272] have used 133Xenon washout which measures 
the disappearance of the isotope injected into adipose tissue where faster disappearance 
reflects higher blood flow in adipose tissue. Using this technique it has been reported 
that ATBF is higher in trained versus sedentary healthy individuals [327, 328]. Given 
this finding, it would be reasonable to assume that exercise training interventions would 
likewise increase ATBF, however the evidence so far is not clear. Sixteen weeks of 
endurance exercise training in young healthy lean men improves aerobic capacity by 
~25%, but does not improve body composition (fat mass or lean muscle mass) or resting 
or epinephrine stimulated ATBF [329]. Similarly, 12 weeks of aerobic exercise training 
in healthy older women produced a significant increase in exercise capacity, but again, 
this improvement was not associated with changes in body composition or resting 
ATBF [330]. There have also been mixed findings regarding the impact of chronic 
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exercise training (12-16 weeks) on ATBF in overweight/obese individuals when 
assessed indirectly using microdialysis [331, 332]. This lack of association between 
chronic exercise training and ATBF may result from indirect blood flow measurements 
which are not assessing flow at the microvascular level (the critical site for nutrient 
exchange). In addition, previous studies have been conducted in healthy subjects where 
the microcirculation is already functioning normally. In contrast, people with T2D have 
impaired microvascular function, which in skeletal muscle, has been shown to improve 
with exercise training. Given this, it was hypothesised that microcirculation in adipose 
tissue may respond in a similar way and that resistance training may help to restore this 
impaired vascular function. 
 
Over the past 15 years it has been demonstrated that microvascular blood flow is 
important in determining insulin’s metabolic effects in skeletal muscle independent of 
changes in total limb blood flow [280, 299, 338, 342, 347, 367-369]. This was made 
possible in part with the adaptation of the CEU technique for skeletal muscle. In the 
present study use of a novel real-time CEU imaging to assess microvascular blood flow 
responses in adipose tissue. This is an important distinction from other techniques 
because nutrient exchange occurs at the microvascular level. The CEU technique has 
the capacity to isolate the measurement to the microcirculation and dissect different 
perfusion components – in particular, microvascular blood volume (MBV – the number 
of capillaries being perfused), microvascular flow velocity ( –the filling rate of the 
capillaries being perfused) and microvascular blood flow (MBF – which is the product 
of MBV and ) [280, 281]. Thus using this technique it was possible to dissect different 
adipose tissue microvascular responses in people with T2D and which components are 
altered following six weeks of RT. It was a surprise to find that adipose tissue 
microvascular responses (MBV,  and MBF) were not altered following RT.  
 
There are several possibilities as to why there were not any significant improvements 
in adipose tissue microvascular responses in adipose tissue of people with T2D 
following RT. Firstly, the length of training may not have been sufficient to cause 
improvements in adipose tissue MBV or MBF at rest or during the OGC. This is 
particularly important given that it was observed in Chapter 5 that the degree of obesity 
is negatively associated with adipose MBV and MBF. Secondly, this type of exercise 
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training (RT rather than aerobic exercise) may not be sufficient to sensitize the 
microcirculation to respond to the OGC. Although it has been previously demonstrated 
that marked improvements in skeletal muscle MBF occur following six weeks of RT in 
people with T2D [299], the regulation of  microcirculation in skeletal muscle and 
adipose tissue are clearly different. These tissue specific differences could also be due 
to skeletal muscle and its vasculature being physically trained during RT, whereas 
adipose tissue is “passively trained”. Thirdly, the fat loss (albeit small) in the current 
study may not have caused concomitant microvascular remodelling. It is well known 
that during adipose tissue expansion (hypertrophy) capillary density declines [370] and 
therefore reducing adipocyte size may not necessarily increase capillary density. 
Fourthly, it was observed that following six weeks of RT, circulating TNF and 
sVCAM-1 levels were significantly elevated (Figure 6.3). It is well established that 
high intensity or RT training can promote an acute pro-inflammatory state [325, 371]. 
This pro-inflammatory phenotype in the T2D participants occurred despite avoiding 
exercise (including the RT program) for 48 hrs to returning to the clinic for cardio-
metabolic testing. It has previously been demonstrated that the pro-inflammatory 
cytokine TNF can cause skeletal muscle microvascular insulin resistance in healthy 
rats [372]. Whether the elevated TNF and sVCAM-1 levels observed post-RT caused 
microvascular insulin resistance in adipose tissue is not known and warrants further 
investigation.  In addition, our study focused on subcutaneous adipose tissue. Whether 
central (visceral) adipose tissue also displays the same microvascular abnormalities 
before and after RT is yet to be confirmed. It is known that adipose tissue blood flow 
increased during exercise in healthy people [251], so it is possible that six-week RT 
might not have changed baseline adipose tissue blood flow, but might still have 
improved adipose tissue blood flow during exercise. 
 
In summary, the current chapter demonstrates that improvements in insulin sensitivity, 
glycaemic regulation, circulating lipids and body composition in people with T2D 
following six weeks of RT are not conditionally linked to improvements in MBV and 
MBF in adipose tissue. A pro-inflammatory phenotype after exercise training did not 
explain the lack of adipose microvascular improvements with RT. Improving 
microvascular function in adipose tissue of people with T2D as a novel approach to 
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prevent pathogenesis of obesity related complications such as IR, dyslipidaemia and 
glucotoxicity is uncertain.  
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Chapter 7: Study Significance and Future Directions 
 
7.1 Key findings 
 
Microvascular blood flow is important to deliver key nutrients (e.g. oxygen, lipids and 
glucose) and hormones to (e.g. insulin) and remove waste products from adipose tissue. 
Total ATBF increases after a meal, and this response is impaired in obesity and T2D. 
Microvascular blood flow is more important than total blood flow for nutrient exchange 
in many tissues, however it was not known whether microvascular blood flow in 
adipose tissue is altered by meals or T2D. Chronic exercise training improves 
microvascular blood flow in skeletal muscle of people with T2D. Whether adipose 
tissue microvascular responses are similarly improved following exercise training in 
people with T2D was unknown. The overarching goal of the current thesis was to 
characterise microvascular ATBF responses to a meal in healthy and T2D subjects, and 
determine whether these responses are altered by chronic exercise training. 
 
The first aim characterised adipose tissue microvascular blood flow responses in the 
post-prandial state in healthy people. Adipose tissue microvascular blood flow was 
measured by contrast-enhanced ultrasound (CEU) at baseline and 1-hour after a mixed 
meal challenge or an oral glucose challenge (OGC). Adipose tissue MBV and MBF 
increased to a similar extent with both challenges. This increased microvascular 
perfusion of adipose tissue may improve delivery of key nutrients (e.g. glucose and 
lipid) from the meal for storage in adipose tissue. 
 
The second aim investigated whether people with T2D have an impairment in adipose 
tissue microvascular responsiveness following an OGC, and whether systemic 
inflammation or the metabolic syndrome is associated with an adipose tissue 
microvascular-linked phenotype. Adipose tissue MBV and MBF post-OGC were 
markedly impaired in T2D when compared to healthy controls. These impaired 
microvascular responses in adipose tissue were associated with obesity, insulin 
resistance, hyperglycaemia and dyslipidaemia, but not systemic inflammation.  
 
The final aim determined whether chronic exercise training restores adipose tissue 
microvascular blood flow in people with T2D. Adipose tissue microvascular blood flow 
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was measured by CEU before and after six-weeks (3 days per week) of a fully 
supervised resistance training program. Insulin sensitivity, glycaemic regulation, 
circulating lipids and body composition were all improved in people with T2D 
following resistance training. However, these favourable cardio-metabolic outcomes 
were not associated with a paralleled improvement in adipose tissue MBV and/or MBF. 
 
Collectively, this thesis has demonstrated that a mixed meal or an OGC induces both 
MBF and MBV increases in adipose tissue in healthy but not people with T2D, and 
these impairments are not restored by six weeks of exercise training. The dissociation 
of impaired adipose microvascular blood flow from inflammation, but association with 
body fat, glycaemic response and lipid handling provides clues about the role of adipose 
tissue microvascular blood flow in metabolic derangements associated with T2D. In 
particular, changes in adipose tissue microvascular blood flow in obesity/T2D may 
affect lipid deposition prior to altering adipose tissue hypoxia and inflammation. 
 
7.2 Summary of findings 
 
7.2.1 Adipose tissue microvascular blood flow increases in the post-prandial state 
in healthy people 
 
Chapter 3 demonstrated that glucose and insulin levels rose significantly following the 
ingestion of a MMC in healthy people. Adipose MBV significantly elevated 1-hr 
following the MMC when compare to baseline. Adipose tissue MBF was also higher 
compared to baseline but was borderline significant. This microvascular action may 
improve delivery of hormones (e.g. insulin) and nutrients (e.g. glucose and lipids) from 
the MMC to adipose tissue for storage. 
 
Baseline adipose tissue MBV was negatively associated with fasting insulin, but 
positively associated with QUICKI (a surrogate marker of insulin sensitivity). Adipose 
tissue MBV following the MMC was positively associated with diastolic blood pressure 
(DBP). Also, baseline MBF was negatively associated with total body fat (%) and 
truncal fat (%). This suggested that MBF in adipose tissue is lower in people with 
obesity. 
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7.2.2 Adipose tissue microvascular blood flow increases in healthy people 
regardless of macronutrient profile 
 
Chapters 3 and 4 compared the adipose tissue microvascular responses to an OGC and 
a MMC in healthy subjects. Compared with the OGC (which only contains glucose), 
the MMC contains protein, fat, and carbohydrate (including sugars). Blood glucose 
levels were significantly higher after the OGC when compared with the MMC, but both 
MMC and OGC produced a similar plasma insulin response. Importantly, the OGC and 
MMC produced a similar increase in MBV and MBF in adipose tissue of healthy people. 
This study has established for the first time in humans that adipose tissue microvascular 
responses are similar between the MMC and OGC despite very different macronutrient 
profiles and glycaemic loads. Therefore insulin, rather than the composition of the meal, 
may be a key regulator of adipose tissue microvascular blood flow.  
 
7.2.3 Adipose tissue microvascular blood flow is impaired in people with T2D 
 
In chapter 5, the difference in adipose tissue microvascular responses to the OGC was 
compared between people with T2D and healthy subjects. People with T2D had 
significantly higher body weight, BMI, total body fat (%) , trunk fat (%), fasting blood 
glucose, fasting plasma insulin, HbA1c, HOMA-IR, SBP, DBP, serum triglyceride and 
FFAs, and lower HDL and QUICKI when compared with control participants. Blood 
glucose levels in people with T2D were significantly higher than controls at every time 
point during the OGC. The glucose AUC over the 2hrs in the T2D people was 
significantly higher compared with controls. While fasting insulin levels were higher 
in the people with T2D, there were no differences in the time-course of plasma insulin 
levels during the OGC. As such, the insulin AUC for control subjects and those with 
T2D were also similar. However, there were no statistically significant differences 
observed in TNF-α, IL-6, CRP, MCP-1, IL-1β or sVCAM-1 between control subjects 
and those with T2D. 
 
Chapter 4 demonstrated that adipose tissue MBV and MBF were elevated in the post-
prandial state of healthy subjects. However, adipose tissue MBV in controls was 
significantly elevated 1 hr after the OGC and this response was completely absent in 
the people with T2D, being significantly lower than controls at the same time point. 
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Baseline MBF in T2D appeared lower than the control group and was significantly 
lower than controls 1hr into the OGC. This suggested that people with T2D have 
impaired adipose tissue MBV and MBF in response to an OGC compared to healthy 
subjects. 
 
7.2.4 Adipose tissue microvascular blood flow is linked to the metabolic syndrome 
 
Correlations were conducted to determine associations with adipose tissue 
microvascular responses (MBV and MBF) for healthy and T2D subjects. In Chapter 3, 
the degree of obesity was found to be a strong modifier of adipose tissue microvascular 
blood flow. In chapter 4, baseline MBF was also negatively associated with total body 
fat and truncal fat regardless of whether the group were allocated to MMC or OGC. 
Therefore, the greater degree of obesity similarly affects the ability to increase adipose 
tissue microvascular blood flow. 
 
In chapter 5, fasting blood glucose, glucose AUC during the OGC, HbA1c, fasting 
insulin, TG and FFA levels were negatively associated with baseline and/or OGC MBF. 
QUICKI (a surrogate marker of insulin sensitivity) correlated positively with MBF. 
QUICKI was the only metabolic variable that correlated with MBV, being positively 
associated with the MBV response to the OGC. Fasting TG and FFA levels correlated 
negatively with MBF but not MBV. However most of these correlations disappeared in 
healthy people, however a negative correlation was observed between body fat and 
MBF in the healthy group (Chapter 4). Systemic inflammation was not associated with 
adipose tissue microvascular responses. This suggested that impaired microvascular 
function in adipose tissue was associated with obesity, insulin resistance, 
hyperglycaemia and dyslipidaemia, but not conditionally linked to systemic 
inflammation 
 
7.2.5 Resistance training does not improve adipose tissue microvascular blood flow 
in T2D people. 
 
In chapter 5, individuals with T2D had impaired adipose tissue MBV and MBF in 
response to an OGC compared to healthy subjects. Also, previous studies have shown 
resistance training improves skeletal muscle microvascular flow and consequently 
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metabolic function [299]. So, the aim of Chapter 6 was to determine if six weeks of RT 
augments adipose tissue microvascular responses in sedentary people with T2D and 
whether this is paralleled by improvements in IR, hyperglycaemia and dyslipidaemia. 
 
In chapter 6, six-weeks of RT significantly improved metabolic function and reduced 
body fat, but did not improve adipose tissue microvascular blood flow in people with 
T2D. Six weeks of RT significantly reduced fasting blood glucose, HbA1c, glucose 
AUC and HOMA-IR. This was accompanied by a small but significant reduction in 
total body fat, trunk fat and fasting serum triglyceride levels. However, there were no 
significant changes in adipose tissue microvascular blood flow or volume at baseline or 
in response to OGC following RT. 
 
7.2.6 Difference between microvascular responses in adipose tissue and skeletal 
muscle 
 
In chapter 4, it was demonstrated that the OGC and MMC produced a similar increase 
in MBV and MBF in adipose tissue of healthy people. However, work by Russell and 
colleagues have shown that the OGC impaired microvascular responses (both MBV 
and MBF) in skeletal muscle of healthy individuals whereas the MMC was stimulatory 
on MBV and MBF [373]. This may suggest that the mechanism of stimulating blood 
flow in skeletal muscle and adipose tissue is different. Indeed, the mechanism of 
stimulating skeletal muscle blood flow is via insulin causing NO release from the 
endothelium via endothelial insulin receptor, stimulation and Akt activation of eNOS 
[349, 350]. The mechanism of regulating ATBF is complicated. NO blockade blocks 
the ATBF response to oral glucose loading [247], and others [273, 276] have shown 
that ATBF increases in response to insulin infusion. However, increases in adipose 
tissue blood flow in response to infusion of insulin is lower than that of oral glucose 
loading, suggesting additional vasodilatory signals in adipose tissue are involved [273]. 
Notably, β adrenergic receptor antagonism partially blocks the ATBF response to oral 
glucose, suggesting possible sympathetic nervous involvement in the vasodilation [247]. 
 
Moreover, chapter 6 demonstrated that improvements in insulin sensitivity, glycaemic 
regulation, circulating lipids and body composition in people with T2D following six 
weeks of RT are not conditionally linked to improvements in MBV and MBF in adipose 
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tissue. However, Russell et al have recently demonstrated that in addition to these 
cardiometabolic benefits such as improvements in glucose and HbA1c levels, six weeks 
of RT markedly enhances skeletal muscle MBF in T2D subjects in responses to an OGC 
[299]. One possible explanation is that regulation of the microcirculation between 
skeletal muscle and adipose tissue are different. Also, these tissue specific differences 
could also be due to skeletal muscle and its vasculature being physically trained during 
RT, whereas adipose tissue is “passively trained”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Main findings of the current project. Compared with healthy subjects, 
people with T2D had impaired microvascular ATBF and adipose tissue dysfunction, 
but do not display a pro-inflammatory state. Obesity was strongly associated with 
impaired microvascular ATBF and adipose tissue dysfunction, but this impaired blood 
flow was not linked with inflammation. Also, RT didn’t improve adipose tissue 
microvascular blood flow and reduce inflammation, but it significantly reduced body 
fat and improved insulin resistance, hyperglycaemia and dyslipidaemia. Red indicates 
an impairment, green indicates an improvement. 
 
7.3 Clinical implications 
 
There are very few studies investigating microvascular responses in adipose tissue in 
humans. Those who have assessed adipose tissue microvascular responses have focused 
 
Adipose tissue 
dysfunction
Impaired adipose tissue
microvascular blood flow Inflammation
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Obesity
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on microvascular blood volume (MBV) and not microvascular blood flow (MBF). This 
project has demonstrated that both adipose tissue MBV and MBF increased to a similar 
extent with an oral glucose challenge and a mixed meal challenge. This increased 
microvascular perfusion of adipose tissue may improve delivery of key nutrients (e.g. 
glucose and lipid) from the meal for storage in adipose tissue. The possible clinical 
implications of this study could help to understand the role of adipose tissue blood flow 
on nutrient exchange and cardio-metabolic health. 
 
Moreover, compared with controls, there is an impairment in both MBV and MBF in 
adipose tissue of people with T2D. The degree of obesity (independent of T2D) is a 
strong modifier of adipose tissue microvascular blood flow. Therefore, chronic exercise 
training was explored to determine whether improve adipose tissue MBV and MBF in 
people with T2D is linked to better metabolic health. Improvements in insulin 
sensitivity, glycaemic regulation, circulating lipids and body composition in people 
with T2D following six weeks of RT, but these effects are not conditionally linked to 
improvements in MBV and MBF in adipose tissue. As for the clinical complications of 
this study, improving microvascular function in adipose tissue may be a novel approach 
to prevent pathogenesis of obesity related complications such as IR, dyslipidemia and 
glucotoxicity in the future. 
 
7.4 Limitations of this project 
 
A limitation of the study was number of participants. The study should be performed 
with a larger number of participants to make sure similar results are reproduced. This 
would ensure results and significant correlations in healthy and T2D people found in 
the present study were not due to chance. Another limitation of the study was that the 
T2D participants were on a variety of medications when compared to the healthy 
controls. Although all diabetes related medications were omitted for 48hrs prior to 
attending the clinic for testing, participants were still taking other medications (e.g. 
statins and anti-hypertensives) which may have contributed, at least in part, to 
variations in inflammation and blood flow responses between healthy and T2D subjects. 
 
Moreover, another limitation of the study was the temperature of clinic room. All 
patients were tested in the same clinical room with similar temperature settings, but no 
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temperature readings were taken. Thermoregulation may play a role in the adipose 
tissue microvascular perfusion.  
 
Adipose tissue levels of pro-inflammatory markers were not measured, and histology 
was not conducted on adipose tissue to assess the degree of macrophage recruitment 
and activation, or assess adipose tissue oxygenation. In regards to the effect of RT on 
adipose tissue microvascular blood flow study, a limitation of this study was the lack 
of a non-exercising control group. The researcher was also not blinded during the 
analysis. This could potentially introduce a reporting bias which should be removed in 
future studies.  
 
7.5 Future directions 
 
The current thesis demonstrated that the OGC and the MMC produced a similar 
increase in MBV and MBF in adipose tissue of healthy people. However, the 
mechanism of the increase in MBV and MBF in adipose tissue is not fully understood. 
Further studies should investigate how and why the increase in adipose tissue MBV and 
MBF occurs.  
 
Furthermore, people with T2D had impaired adipose tissue microvascular blood flow 
and they were unable to increase their MBV and MBF in response to an OGC. As these 
novel findings were limited to the subcutaneous central adipose tissue, future studies 
should explore the microvascular responses in visceral adipose depot (adipose tissue 
surrounding the abdominal organs).  
 
Studies have suggested that the adipocyte undergoes hypertrophy, insufficient 
microvascular blood supply to the adipocyte leads to hypoxia, macrophage recruitment 
and conversion of macrophages from an inactive state (M2) to an active state (M1) in 
which they are reported to release inflammatory cytokines [85, 127]. However the 
current thesis did not observe higher inflammatory cytokines or a microvascular-linked 
pro-inflammatory condition in the T2D cohort tested. Further studies need to be 
conducted to measure adipose tissue levels of pro-inflammatory markers, or conduct 
histology on adipose tissue to assess the degree of macrophage recruitment and 
activation, or assess adipose tissue oxygenation. 
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Regarding adipose tissue function as a whole, there are several key questions to be 
answered in the future: (1) What is the relationship between insulin resistance and 
impaired adipose tissue microvascular blood flow? (2) Which one occurs first, insulin 
resistance or impaired adipose tissue microvascular blood flow? (3) What is the primary 
cause of reduced adipose tissue microvascular blood flow response? (4) What 
factors/treatments can improve adipose tissue microvascular blood flow in people with 
T2D? Further animal or clinical studies are essential to clarify these issues. 
 
There were no significant improvements in adipose tissue microvascular responses in 
adipose tissue of people with T2D following RT. In the future, the length of training 
should be extended beyond 6 weeks to cause sufficient fat loss to see if improvements 
in adipose tissue MBV or can be observed. Also, further studies should investigate 
aerobic exercise training on adipose tissue microvascular blood flow due to its 
increased need for oxygen (and therefore, increased blood flow) and ability to decrease 
adipose tissue mass. 
 
7.6 Conclusions 
 
● Insulin is a key regulator in adipose tissue microvascular blood flow. 
 
● Impaired microvascular function in adipose tissue during T2D is not conditionally 
linked to systemic inflammation, but is associated with other characteristics of the 
metabolic syndrome (obesity, insulin-resistance, hyperglycaemia and dyslipidaemia).   
 
● Six-week RT does not improve adipose tissue microvascular blood flow of people 
with T2D, however it does significantly improve metabolic function and reduce body 
fat. Inflammation does not play a major role in regulating adipose tissue microvascular 
blood flow. 
 
● Understanding the primary mechanism leading to poor adipose tissue microvascular 
blood flow and how to improve adipose tissue microvascular blood flow in people with 
T2D warrants further investigation. Improving adipose tissue microvascular blood flow 
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might be a new therapeutic target to improve management and co-morbidities 
associated with T2D. 
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